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Summary 
Type 1 diabetes (T1D) is a common multifactorial disease of the immune system and 
insulin-producing pancreatic ~ cells, resulting from numerous, and largely unidentified, 
interacting genetic and environmental factors. Association analyses aim to detect alleles of 
DNA polymorphisms, mostly single nucleotide polymorphisms (SNPs), that contribute to 
disease development, thereby revealing the mechanisms underlying these complex 
phenotypes. Since there are at least 25,000 genes in 3 billion base pairs of the human 
genome and the technology available to determine allele identities in large numbers of 
individuals is limited due to cost and feasibility, these studies have been restricted to 
candidate genes thought to function in pathways relevant to the disease or to chromosome 
regions identified by prior genetic linkage studies. I examined the feasibility of association 
mapping in linked regions and showed that surprisingly strong allelic effects are expected 
from the disease variants contributing to linkage. Association mapping in linked regions 
could therefore be successful with moderate and feasible sample sizes, provided gene-gene 
and gene-environment interaction effects operate at relatively modest levels. A key 
question in indirect association or linkage disequilibrium (LD) mapping is the density of 
SNP maps that should be constructed. Simulated sampling of experimental data showed 
that, in the LD mapping of high frequency (2: 10%) disease variants, while sparse SNP 
maps are of some value, comprehensive analyses require SNP map densities of greater than 
one SNP per kb in some parts of the genome. The study of four candidate genes/regions 
provided some positive evidence for T1D associations with the Human Endogenous 
Retrovirus K18 (HERV-K18) I CD48 locus (chromosome lq23) and with the vasoactive 
intestinal peptide (VIP) locus (chromosome 6q25), but not with SNPs flanking D2S152 on 
chromosome 2q31 (IDDM7) or with SNPs in two genes on chromosome 6q27 (IDDM8). 
These findings should be followed up using other datasets to establish their validity. A 
model presented here on the genetic architecture of common diseases, and a discussion on 
the relationships between LD statistics D' and r2, will assist in the planning and analysis of 
future whole genome association studies, the feasibility of which is rapidly improving. 
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Chapter 1 Introduction 
1.1 Epidemiology of Type 1 Diabetes 
Type 1 diabetes (TlD) is a multifactorial disease resulting from interactions between 
genetic and environmental factors. It is caused by the T-cell mediated destruction of 
pancreatic islet ~ cells leading to insulin deficiency. The prevalence of TlD varies 
worldwide and is approximately 0.4% in western societies (Karvonen et al. 2000). Disease 
onset is generally in childhood but can occur much later in life. TlD patients require life 
long insulin replacement for the maintenance of adequate cellular energy and blood sugar 
levels. Long-term complications of the disease include diabetic neuropathy, nephropathy 
and retinopathy, and increased risks of cardiovascular problems such as strokes and 
myocardial infarcts. 
TlD has a genetic basis (Rich 1990; Vyse and Todd 1996). The disease has a sibling 
recurrence risk, As, defined as the risk of developing the disease in a sibling of an affected 
individual relative to that of the normal population, of approximately 15. Segregation 
analyses demonstrated that while TlD inheritance support the existence of a major gene, 
many other genes also contribute to the disease (Goodman and Chung 1975; Zavala et al. 
1979). The major TlD genetic locus has been discovered and is at the major 
histocompatibility complex (MHC) on human chromosome 6p21 (Cudworth and Woodrow 
1974; Nerup et al. 1974). Two other genes, Insulin (INS) and CTI.A-4, have TlD 
association substantiated in multiple datasets and populations (Bell et al. 1984; Nistico et 
al. 1996; Ueda et al. 2003). 
Despite its strong genetic predisposition, however, the long-term TlD disease concordance 
rate is about 50% for monozygotic twins suggesting that environmental factors influence 
significantly the penetrance of susceptible alleles (Redondo et al. 2001). Increased TlD 
prevalence in western societies during the later half of the twentieth century suggests that 
there is a contribution from modem lifestyles (Gale 2002). Environmental factors such as 
the time of cereal exposure in infants have been associated with the disease (Norris et al. 
2003; Ziegler et al. 2003). Genetic and environmental factors may act interactively to 
cause TlD, perhaps similar to the interaction between gluten and susceptible human 
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leukocyte antigen (HLA) genotypes to produce coeliac disease (Falchuk et al. 1972). A 
general reduction in infections in affluent developed countries may also contribute to the 
increasing incidence, the so called "hygiene hypothesis" (Strachan 1989; Todd 1991). 
1.2 Genetic Mapping of Common Multifactorial Diseases 
The genetic mapping of TlD and other common diseases, such asthma and high blood 
pressure, is complicated by the problem that these diseases result from multiple interacting 
genetic and environmental factors each contributing weakly to the final phenotype. 
Disease heterogeneity and inter-population differences are also likely. Disease gene 
mapping can be candidate or genome based, and association and linkage methods are 
commonly used. Animal modelling and gene expression studies further extend our 
knowledge of disease aetiology. 
Linkage studies examine the familial cosegregation of genetic markers and disease 
phenotypes. It has been highly successful in the study of Mendelian disease caused by 
highly penetrant mutations that show 100% concordance between genotypes and 
phenotypes. Linkage with the use of affected sib-pairs (ASP) (Penrose 1953) has been 
favoured in studying common multifactorial diseases owing to its robustness to problems 
such as disease heterogeneity. Since large pedigrees with several affected individuals for 
complex diseases are rare owing to diseases' reduced penetrance and multigenetic 
aetiology, nuclear families consisting of parents and ASPs are the most available sampling 
configuration. When ASPs share 1 and 2 chromosomes identical by descent (IBD) greater 
than the expected probabilities of 0.5 and 0.25 respectively, then linkage between test 
markers and disease locus is demonstrated. It has been argued that potential genomewide 
multiple comparisons need to be considered in the interpretation of significant results 
(Morton 1955; Lander and Kruglyak 1995). The main drawbacks of ASP linkage 
approaches are their limited resolution and low power when compared to association 
studies (Risch and Merikangas 1996), except in cases of multiple rare disease susceptible 
variants in each locus and in some models of epistasis. Genomewide linkage studies have 
been conducted for many common diseases (Davies et al. 1994; Daniels et al. 1996; Blouin 
et al. 1998; Krushkal et al. 1999), but there are very few reproducible positive results 
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(Altmuller et al. 2001). In contrast, linkage mapping in disease model organisms, in which 
the parental strains are homogeneous for all loci and bred under uniform conditions, have 
been more successful in informing of the location of the susceptible loci (Jacob et al. 1991; 
Todd et al. 1991). 
Association studies examine association between marker frequencies and disease 
phenotypes, with cases and controls being the most common design. The main advantages 
of association studies are robustness to disease heterogeneity, higher statistical power and 
ease of sampling. A drawback of the case-control approach is the possibility of population 
stratification resulting in false positive findings, which occurs when cases and controls are 
genetically mismatched and differences noted between them are due to background genetic 
differences not related to the trait of interest (Pato et al. 1993). Stratification can be 
resolved by using family based association approaches such as the transmission / 
disequilibrium test (TDT) (Spielman et al. 1993). Although the TDT was originally 
devised as a test for linkage in the presence of association, related methods can provide 
valid tests of association in families with multiple affected offspring (Martin et al. 1997). 
Family-based association studies can use the same subjects as those for linkage scans, 
making additional sampling unnecessary. However, these designs are less efficient than 
the use of cases and controls (Morton and Collins 1998), difficult to ascertain in late onset 
diseases, and suffer from potentially biased results in the presence of genotyping errors 
(Gordon et al. 2001). With the prior assessment of population structures (Pritchard and 
Rosenberg 1999), the problem of population stratification may be corrected during data 
analyses, perhaps making family based designs unnecessary (Devlin and Roeder 1999; 
Hoggart et al. 2003). 
Candidate gene approaches involve selection of candidate genes based on prior evidence of 
their involvement in the disease. It has traditionally been the favoured approach owing to 
the high cost and low feasibility of genomewide methods. However, even though the 
approach has firmly implicated a handful of genes with complex diseases (Ioannidis et al. 
2003), it came at the cost of numerous null and borderline results (Emahazion et al. 2001; 
Ioannidis et al. 2001), with a significant proportion unpublished. Owing to the numerous 
and unknown candidate genes and physiological pathways for any complex trait, and the 
large number of genes expressed in any system (Dempsey et al. 2001), gene selection is 
difficult. Furthermore, because of the underlying uncertainties, the functional candidate 
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approach does not informatively accumulate or provide exclusion mapping data. Despite 
these difficulties, if gene selection is possible with good prior odds, candidate approaches 
will continue to be fruitful. Chapter 4 will discuss further the selection of candidate genes 
and presents the study of four T1D candidate genes/regions. 
The attempted mapping and fine mapping of complex disease genes has followed the 
classic Mendelian disease route (Rommens et al. 1989): linkage mapping followed by 
association analyses in the most disease linked regions. This two-staged approach has 
provided a few positive results in common diseases, and revealing novel disease 
mechanisms (Hugot et al. 2001; Ogura et al. 2001; Walley et al. 2001). The major 
limitation of the approach is that reliable linkage is difficult to establish owing to the weak 
linkage effects of most disease variants (Risch and Merikangas 1996; Altmuller et al. 
2001). If reliable linkage can be found then it provides some information on both the 
position and the genetic effect of the underlying disease loci. Chapter 2 will discuss 
advantages and disadvantages of the two-staged approach, and examine the potential for 
association mapping in a linked region under a variety of scenarios. 
1.2.1 Linkage disequilibrium 
Linkage disequilibrium (LD) occurs when alleles of different polymorphisms are 
associated in the presence of linkage. Consider two linked single nucleotide 
polymorphisms (SNPs), with alleles (A, a) and (B, b) respectively, four possible haplotypes 
can exist: AB, Ab, aB and ab. Letf(X) denote the frequency of the X allele or haplotype. 
In the case of equilibrium, alleles of the two SNPs distribute independently and the 
frequency of haplotypes can be directly predicted by the frequencies of alleles (e.g.f(AB) = 
f(A) xf(B)). LD is the deviation from that. Mutation and population admixture can 
introduce SNPs to a population limited to one or a few haplotypes and thus create LD. The 
main determinant in the decay of LD is recombination. Starting from complete LD 
(below), recombination eventually leads to linkage equilibrium. LD is influenced by other 
factors such as genetic drift (natural random changes in allele and haplotype frequencies), 
population histories and demography (Shifman et al. 2003), selection (Sabeti et al. 2002), 
and chromosome recombination events such as gene conversion (Frisse et al. 2001). 
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A number of statistics have been devised to measure LD (Devlin and Risch 1995). The 
two most commonly used of these are D' and r2. Both these statistics are related to the 
basic unit of LD, D, which measures the deviation of haplotype frequencies from the 
equilibrium statef(AB) - f(A) x f(B) = 0 (Lewontin and Kojima 1960). 
D = f (AB) - f (A)f(B) 
D' is ratio of D compared to its maximum value Dmax (Lewontin 1964). It is largely 
dependent on the recombination history. D' = 1, denotes complete LD. Recombination 
decays D' and at equilibrium D' = 0. 
D' =__!!_ 
Dmax 
(1) 
r2 is the statitical coefficient of determination and can be written as (Hill and Robertson 
1968): 
D2 
r2 = --------
f (A)f (a)f (B)f (b) 
(2) 
When r2 = 1, knowing the genotypes of alleles of one SNP is directly predictive of the 
genotypes of another SNP. r2 is dependent on both the recombination history and allele 
frequencies, and is of particular importance in genetic mapping as it is inversely related to 
the required sample size for association mapping, given a fixed genetic effect (Sham et al. 
2000; Pritchard and Przeworski 2001). For example, if only one of two SNPs were 
genotyped and r2 between the SNPs is 0.5, then to provide the same statistical power for 
the ungenotyped SNP compared to if r2 = 1, the sample size will need to be doubled. 
D' and r2 are closely related and can be written in terms of each other and allele 
frequencies . By rearranging equation (1) and substituting D into equation (2), 
2 . (D' Dmax )2 
r - · --------'="- --f ( A) f (a) f (B) f ( b) 
Without loosing generality, alleles A and B can be chosen such that D :::: 0 andf(A) :::: f(B) . 
Hence, 
5 
and 
Dmax = f(a)f (B) 
r2 = (D')2 x f(a)f(B) 
f (A)f(b) 
(3) 
Formula (3) shows a deterministic relationship exists between D', r2 and allele frequencies. 
Since f(A) ?_f(B), r2 has the upper bound of (D')2, and reaches it only when frequencies of 
the positively correlated alleles are equal. Within a genomic region where SNPs exhibit 
high D' with each other, frequencies of positively correlated alleles, and not physical 
distance, predict r2. Although D' per se is insufficient to ensure high r2, it will, 
nevertheless, delimit r2 and the potential for useful LD. A useful cut-off for D' might be 
0.7, as for lower D' values, r2 will be less than 0.49 and sample sizes will need to be more 
than doubled to maintain the same statistical power. Both LD statistics suffer from 
sampling biases given a small number of individuals (Weiss and Clark 2002). Confidence 
intervals for D' has been used by some investigators (Gabriel et al. 2002). The reliability 
of r2 is examined as a part of Chapter 3. 
Two different, but complementary, approaches to association mapping have been termed 
"direct" and "indirect" (Collins et al. 1997). The direct approach examines polymorphisms 
that affect the expression or biochemical properties of proteins, and hence are primary 
candidates for diseases aetiology (Sobell et al. 1992; Botstein and Risch 2003). The 
indirect approach utilizes LD, and aims to detect disease association for variants both 
directly and not directly analysed. It requires the initial detection and validation of SNPs 
throughout genomic regions of interest, followed by assessments of LD relationships. The 
knowledge of LD and haplotype relationships allows a subset of markers (haplotype tag 
SNPs or htSNPs) to capture essential information of all SNPs identified (Johnson et al. 
2001). In large-scale association studies, genotyping htSNPs alone can lead to reductions 
in laboratory efforts and costs while maintaining statistical power (Carlson et al. 2003; 
Chapman et al. 2003; Stram et al. 2003). The proportion of SNPs that need to be 
discovered and validated, · and the number genome wide htSNPs will be examined in 
Chapter 3. 
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1.2.2 Linkage disequilibrium in the human genome 
The knowledge of LD and distribution of haplotypes in the human genome will aid in 
planning indirect genomewide association studies (International HapMap Consortium 
2003). Until recently, most studies on LD focused on its averages (Eaves et al. 2000; 
Reich et al. 2001). Studies of LD using higher density of markers, suggested that it is 
organised into blocks of SNPs in high LD throughout the human genome (Daly et al. 2001; 
Jeffreys et al. 2001; Patil et al. 2001; Gabriel et al. 2002). While there are SNPs not in LD 
with any others, LD blocks can extend over 800 kb (Dawson et al. 2002). It has also been 
suggested that these blocks are limited in diversity and generally contain three to six 
common haplotypes (Daly et al. 2001; Patil et al. 2001; Dawson et al. 2002; Gabriel et al. 
2002). In a study of 51 autosomal regions, Gabriel et al. (2002) noted that 40% and 57% 
of sequences were found in blocks of> 30 kb in African (Y oruban Nigerians and African 
Americans) and non-African populations (Asian and European Americans) respectively. 
Compared to Asian and European populations, LD blocks in African populations were in 
general smaller and more haplotypically diverse (Gabriel et al. 2002). The appearance of 
blocks has been suggested to be the result of more recombination between and less within 
regions. Sperm typing and familial segregation studies suggested that some of the breaks 
in LD correspond to genomic hotspots where meiotic recombinations happened more 
frequently (Jeffreys et al. 2001; Kauppi et al. 2003; Twells et al. 2003). However, given 
the same LD data, different definitions can result in the partitioning of different blocks. 
Taken together with the observation that blocks can overlap, this suggests that 
recombination hotspots vary in intensity, and that the observed LD pattern across sites of 
historical recombination vary according to population demographics and markers density. 
Coalescence simulation suggested that hotspots are not necessary for the observation of 
block like LD (Wang et al. 2002; Phillips et al. 2003). 
Successful indirect association mapping requires test markers (or their haplotypes) to 
exhibit correlative LD (high r2) with disease causing variants . Therefore, simply knowing 
the extent of LD is insufficient, as given LD block of any size, variations could exist in 
both number of SNPs and haplotype structure. In Chapter 3, the issue of marker density 
requirement for indirect association mapping will be examined. 
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1.2.3 Fine mapping 
Fine mapping refers to the identification of the most likely disease predisposing variants 
(the "causal variants") after the initial detection of association to a marker. The process 
involves (i) delimiting the genomic extent of LD, and, thus defining regions of interest, (ii) 
discovering and validating all variants within the associated regions, and (iii) identifying 
candidate causative variants from those in LD. Several challenges exist in this process. 
Delimiting LD should be more achievable for high frequency SNPs than for young rare 
mutations, or microsatellites, which are known to have longer range LD. Owing to the 
nature of recombination and population histories, closely located SNPs can have different 
extents of LD. Identifying polymorphisms within a region could face technical problems 
in the presence of genomic repeats or high GC content. Distinguishing disease causal 
variants from those in LD can be troublesome if LD is strong. Studying populations with 
different LD relationships might, therefore, be useful, but is confounded by differences in 
genetic and environmental backgrounds. Another approach is to model the genetic effects 
of different variants in a large population set, and see if the addition or removal of 
additional variants changes the overall effect of disease association (Cordell and Clayton 
2002; Ueda et al. 2003). While that approach can greatly reduce the number of candidate 
disease causing variants, it is limited by the presence of very strong correlative LD (i.e. 
high r2) as differences between polymorphisms lie with a few individuals (Ueda et al. 
2003). Using our understanding of biology, the location of variants might suggest their 
biological relevance. Functional analyses and animal modelling can provide further 
supportive evidence (Complex Trait Consortium 2003). 
1.2.4 Allelic architecture 
The allelic architecture refers to the number of disease variants, their allele frequencies and 
the risks they confer. Through the determination of statistical power, it determines the 
likelihood of success for different genetic mapping approaches. 
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1.2.4.1 Distribution of disease allele frequencies 
High frequency disease variants with minor allele frequencies (MAF) of greater than 10 % 
can be readily identified by sequencing a small number of individuals. Using practical 
sample sizes, they can then be studied via direct or indirect association mapping 
approaches, such as using the information from the proposed HapMap project 
(International HapMap Consortium 2003). Lower frequency disease variants with MAF 
between 1 % and 10% can also be identified, but are less amenable to approaches reliant on 
high frequency haplotypes or high frequency SNPs currently in public databases. An 
example of low frequency variants causing disease was the discovery of three 
polymorphisms with population MAP between 1 % to 5% in the NOD2/CARD15 gene on 
chromosome 16 as major risk factors of Crohn's disease (Hugot et al. 2001; Ogura et al. 
2001). The genetic effects of the disease susceptible variants were high, compared to the 
low risk homozygotes, genotype relative risks were 3 and 38 for susceptible heterozygotes 
and homozygotes respectively. Rarer disease variants of less than 1 % frequency are not 
readily mappable, except if they have very high disease penetrance, i.e. if they are near 
Mendelian. This is because such rare variants are both difficult to detect (Glatt et al. 2001) 
and require very large sample sizes to provide statistical power in association studies. 
Two polarised views dominate much of the literature on the allelic architecture of common 
diseases. The Common Disease/Common Variant (CDCV) hypothesis proposes that 
common diseases are a result of common variants (Reich and Lander 2001). Under this 
model, disease outcome is considered to be the joint action of several common variants, 
and affected individuals share a significant proportion of disease alleles. The extreme 
alternative to CDCV is the classic disease heterogeneity (or multiple rare variant) 
hypothesis, which proposes that diseases are due to different risk factors in different 
individuals, and that disease susceptible alleles have very low population frequencies. 
Heterogeneity models predict linear correlations between plienotypic and genetic 
similarities (Fisher 1918). Examinations of this correlation in different common diseases 
yielded different results. Heterogeneity models were best demonstrated in some cancers 
where disease risk declines linearly with genetic relatedness (Risch 2001). However, in 
TlD, the rate of fall of familial recurrence risk with distance of relationship is non-linear 
(Rich 1990), making heterogeneity less likely. 
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Arguments used to support different hypotheses on allelic spectrum have largely been 
based on population genetic theories and may, therefore, be influenced by their underlying 
assumptions (Pritchard 2001; Reich and Lander 2001). However, empirical evidence 
suggests that both high and low frequency alleles contribute to common diseases (Wooster 
et al. 1995; Todd 2001; Lohmueller et al. 2003). It might be preferable to avoid the 
polarisation of rare versus common disease susceptible alleles and instead consider the 
allelic spectrum of disease variants from that of allelic spectrum in general (Figure 1.1). 
The most neutral hypothesis would, therefore, be that the allelic spectrum of disease 
variants is the same as the general spectrum of all variants (Wang and Pike in press). 
Under this neutral model, although most variants would be rare, SNPs with MAF > 1 % 
would account for greater than 90% of genetic differences between individuals and should 
contribute significantly to phenotypes (International HapMap Consortium 2003). 
Comparing with the overall spectrum, CDCV could be considered as a common shift, and 
the disease heterogeneity model a rare shift (Figure 1.1). If disease variants tend to occur 
in the coding regions of the genome (Botstein and Risch 2003; Clark 2003), then a rare 
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Figure 1 Potential allelic spectra of human diseases. (a) An allelic spectrum is similar to that of the genome 
as a whole. (b) A "rare shift" leading to disease heterogeneity. (c) A strong "common shift" and disease 
alleles tend to be have high population frequencies. 
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shift would also be the result. Additional evolutionary forces can cause spectra shifts as 
well (Pritchard 2001). Furthermore, the allelic spectrum will be different for different 
common diseases. For the genome as a whole, it has been predicted that of the expected 
11 million SNPs with MAF > 1 %, approximately of them half have MAF > 10%, and the 
other half have MAF between 1 % and 10% (Kruglyak and Nickerson 2001). Given that 
the number of disease variants conferring mild to moderate risks may be large (next 
section), then unless shifts in allelic spectra are severe, large-scale association mapping 
methods targeted at either end of the spectrum will yield positive results. 
1.2.4.2 Distribution of genetic risks 
An issue related to the distribution of allele frequencies is the distribution of genetic risks 
conferred by individual variants. Twin and familial studies showed that the patterns of 
inheritance of most common diseases indicate the existence of multiple variants. While it 
is not possible to predict the exact distribution of allelic effects for a given disease, several 
lines of evidence point to potential underlying distributions. Using mutagenesis, selection 
and linkage approaches, studies of quantitative trait loci (QTLs) in Drosophila, crops and 
livestock suggested that the distribution of the strengths of genetic variants may follow 
curved L shaped distributions, which have been modelled by exponential or gamma 
distributions , with few genetic loci of large effects and numerous loci of small effects 
(Robertson 1967; Paterson et al. 1991; Mackay et al. 1992; Hayes and Goddard 2001; 
Barton and Keightley 2002; Wright et al. 2003). These results are consistent with current 
evolutionary theories where by applying molecular drifts and mutational effects into 
classic models of adaptation (Fisher 1930), the expected distribution of QTL effects is 
exponential (Orr 1~98). Genomewide scans for linkage in the nonobese diabetic (NOD) 
mouse (Vyse and Todd 1996; Todd and Wicker 2001), the experimental model for TlD, 
also support the idea of a few major loci of strong effects (MHC/Iddl, Il2-Il21/ldd3) and a 
larger number of loci with smaller effects (Risch et al. 1993). The potential for a large 
number of variants contributing to human phenotypes is further supported by the findings 
that allelic variations frequently influence gene expression (Hoogendoorn et al. 2003; Lo et 
al. 2003), and may, therefore, contribute to phenotypes. 
Results from linkage studies in human have been largely disappointing in finding 
significant and reproducible peaks (Altmuller et al. 2001). Genetic loci identifiable by 
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linkage require very large effects in the population (Risch and Merikangas 1996; Knapp 
1999) and failures in linkage studies suggest that such loci are uncommon. Furthermore, 
the effects of the few confirmed linked loci are not sufficient to explain the familial 
clustering of common diseases. While some of the residual familial clustering would be 
environmental, much of it may be explained by genetic loci with modest effects 
(Sadovnick et al. 1996; Peto et al. 2000). 
In association analyses only a few variants with large disease risks have been identified. A 
larger number of variants with weaker effects, however, have been substantiated in disease 
aetiology in meta-analyses or in large case-control studies (Ioannidis et al. 2003; 
Lohmueller et al. 2003). Nevertheless, meta-analyses based on published data could suffer 
from publication bias with the tendency for journals to reject small studies with null 
results. Associated disease susceptible variants so far have typical allelic odds ratios in the 
order of 1.2 to 1.5 (Ioannidis et al. 2003). Such loci contribute very little to familial 
recurrence risks (Rybicki and Elston 2000). For example, assuming a multiplicative model 
for the effect of alleles, a disease susceptible allele of 10% in frequency and conferring a 
1.5 fold increases in risk, has a As of only 1.02. Given that the familial clustering in 
complex diseases can be quite strong (Vyse and Todd 1996; Altmuller et al. 2001), the 
number of loci with weakly to familial recurrence risks but have detectable effects in the 
population may, therefore, be large, although the exact breakdown of the residue familial 
recurrence risks will depend on if loci act heterogeneously or interactively (Risch 1990). It 
has been estimated that over 50 QTLs might be required to explain 50% of blood pressure 
variance (Rudan et al. 2003). In the case of T1D, which the total As is 15 and the major 
loci, HLA, have an estimate As of 3, combined linkage studies suggest that there may be no 
more than one other loci with As> 1.3 (Cox et al. 2001; European Consortium for IDDM 
Genome Studies 2001). Therefore, a large number of weaker loci would be required to 
explain the residual As, even if this was affected by familial .environmental factors. 
Experiments planned with power to identify disease susceptible variants with allelic odds 
ratios of 1.2 to 1.5 may provide the most optimum trade-off between the likelihood of 
success due to number of potential underlying variants and cost of obtaining and 
genotyping samples, given today' s costs and technologies. 
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1.3 Identified T1D Loci 
A large number of genetic loci have shown some linkage or association with TlD, but the 
only firmly established associations are HLA genes, INS and CLTA-4 (Cudworth and 
Woodrow 1974; Nerup et al. 1974; Bell et al. 1984; Nistico et al. 1996; Ueda et al. 2003). 
Genomewide linkage scans found a number of loci showing some evidence of linkage to 
TlD and some have been followed up (Table !)(Davies et al. 1994; Concannon et al. 1998; 
Mein et al. 1998; Cox et al. 2001; European Consortium for IDDM Genome Studies 2001). 
Loci that showed at some stage significant linkage with TlD, or evidence of linkage and/or 
transmission disequilibrium in more than one independent data set were assigned IDDM 
(insulin dependent diabetes mellitus) numbers. 
Table 1.1 Loci with significant linkage achieved in any one ASP linkage study. 
Cytogenetic IDDM First achieved significant Other evidence (independent 
Location Number linkage, P S 2.2 x 10-5 or overlapping) 
6p21 IDDMJ 
6q21 IDDM15 Delepine et al. ( 1997) Concannon et al. (1998); 
ECIGS* (2001) 
6q22-q24 IDDMS Luo et al. (1996) Davies et al. (1994) 
6q27 IDDM8 Luo et al. (1996) Cox et al. (2001); Davies et 
al. (1996); Luo et al. (1995) 
lOcen IDDMJO Mein et al. (1998) Cox et al. (2001); Hashimoto 
et al. (1994) 
llql3 IDDM4 Luo et al. (1996) Davies et al. (1994); 
Hashimoto et al. (1994) 
16p ECIGS* (2001) Cox et al. (2001) 
16q22-q24 Mein et al. (1998) 
18q12-q21 IDDM6 Mein et al. (1998) Merriman et al. (2001) 
Xpll-p21 Zavattari et al. (2000) ECIGS* (2001) 
* European Consortium for IDDM Genome Studies. 
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1.3.1 Major Histocompatibility Complex 
Designated IDDMJ, the most important TlD susceptibility locus identified to date is the 
MHC I HLA. The locus specific As for this chromosome region is 2.5 - 3.1 and the risk of 
disease for HLA identical sibling of an affected individual is about 20% (Davies et al. 
1994). The locus was first implicated in TlD via candidate association and linkage studies 
(Cudworth and Woodrow 1974; Nerup et al. 1974; Barbosa et al. 1978). Susceptible and 
protective variants were later identified through direct sequencing (Todd et al. 1987). 
Some of these variants are also implicated in other autoimmune diseases (Todd et al. 1988) 
and in animal model of disease (Hattori et al. 1986; Wicker et al. 1987). ASP genome 
scans for TlD by Davies et al. (1994) and Hashimoto et al. (1994) identified the MHC as 
most important genetic locus for the disease, and the finding has been consistently 
replicated (Cox et al. 2001; European Consortium for IDDM Genome Studies 2001). 
Using MHC as an example, Herr et al. (2000) illustrated the utility of the two-staged 
linkage followed by association mapping approach in identifying disease genes for TlD -
narrowing the region of association to only 85 kb of DNA, which contained the class II 
genes. 
The human MHC is on chromosome 6p21, spans 3.6 Mb and contains 224 identified genes 
many with known or suspected immunological functions (The MHC sequencing 
consortium 1999). HLA genes can be divided into three classes: I, II and III. Class I and II 
genes produce molecules that are involved in antigen presentation. Peptides, either self 
(during thymocyte selection for example) or foreign (during infection), bound to MHC 
class I molecules are recognised by CD8 T cells, whereas those bound to MHC class II 
molecules by CD4 T cells. MHC genes and molecules are highly polymorphic leading to 
differences in peptide binding and interaction with T-cell receptors. MHC and T-cell 
receptor interactions are important for the determination of self and non-self. 
Autoimmunity can result from alterations in this process. 
Polymorphisms in HLA class II genes and. molecules are associated with TlD. Differences 
in frequencies of HLA alleles and haplotypes may explain population differences in the 
incidence of the disease (Bao et al. 1989; Dorman et al. 1990; Park et al. 2000). The major 
antigen presenting molecules are encoded by the class II genes include a and f3 chains of 
DP, DQ and DR. HLA-DR3 and HLA-DR4 haplotypes confer significant disease 
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Table 1.2 TlD risk associated with HLA-DR and HLA-DQ haplotypes. 
(Cucca et al. 2001) 
T1D risk 
Very high 
Intermediate 
Very low 
(protective) 
DR4 
DR4 
DR3 
DR4 
DR4 
DR4 
DRS 
DR6 
DR9 
DRl 
DR2AZH 
DR4 
DR7 
DR4 
DR4 
DR6 
DRlO 
DR6 
DRS 
DR2 
DR7 
DR6 
DRBl DQAl DQBl 
0405 0301 
0401 0301 
0302 
0302 
0301 0501 0201 
0404 0301 0302 
0402 0301 0302 
0405 0301 0201 
0008 0401 0402 
1302 0102 0604 
0901 0301 0303 
01 0101 0501 
1601 0102 0502 
0401 0301 0301 
0701 0201 0201 
0405 0501 0301 
0403 0301 0302 
1301 0103 0603 
1001 0101 0501 
1303- 1305 0501 0301 
11-12 0501 0301 
1501 0102 0602 
0701 0201 0303 
1401 01 0503 
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Odds Ratios for 
Transmissions 
95% Cl 
10.8 5.6-20.6 
7.2 4.6- 11.5 
4.3 2.9-6.3 
4.1 2.3- 7.1 
3.1 1.4- 6.8 
2 0.7-5.6 
1.6 0.8- 3.1 
1.3 0.6-2.7 
1.2 0.5- 2.9 
1 
0.8 0.5-1.2 
0.8 0.4-1.5 
0.5 0.3- 0.9 
0.4 0.1-1.3 
0.5 0.1-1.4 
0.4 0.2-1.1 
0.2 0.05-0.9 
0.3 0.1- 1.2 
0.2 0.1-0.3 
0.04 0.01- 0.1 
0.1 0.01- 0.6 
0.1 0.01-0.4 
susceptibility (Table 1.2). Other HLA haplotypes may have susceptible or protective 
effects. Interestingly, protective alleles exhibit dominant effects over susceptible alleles. 
Cucca et al. (2001) provided evidence for a joint action of the class II peptide-binding 
pockets Pl, P4 and P9 in disease susceptibility and resistance with a main role for P9 in 
DQ and for Pl and P4 in DR. An important protective polymorphism is the DQ P9 
aspartic acid at position 57 of the HLA-DQ ~ chain, corresponding to DQ~l *0602 allele 
(Todd et al. 1987; Morel et al. 1988). Its mechanism of protection has now been modelled 
by its role in the structure of pocket 9 (Corper et al. 2000; Cucca et al. 2001; Lee et al. 
2001). The structural studies have also suggested that particular~ cell antigens, such as 
preproinsulin (PPI), are involved in dominant mechanisms of self-tolerance. However, 
despite its strong effects, IDDMI !HLA is insufficient to explain the genetic risk of TlD, 
and a child in the population with the susceptible DR3/4 is at much lower risk of 
developing the disease than a DR3/4 child of a TlD parent (Thomson et al. 1988), 
suggesting the importance of other genes. 
1.3.2 Insulin VNTR 
A variable nucleotide tandem repeat (VNTR) polymorphism upstream to INS is associated 
with TlD (Bell et al. 1984). The INS region has been designated IDDM2. In Europeans, 
INS VNTR alleles divide into two discrete size classes. Class I alleles (26 to 63 repeats) 
predispose to TlD, while class III alleles (140 to more than 200 repeats) are protective 
(Julier et al. 1991; Bennett et al. 1995). Linkage between INS and TlD has also been 
demonstrated (Spielman et al. 1993; Davies et al. 1994). Analyses of expression of insulin 
in human fetal thymus found that compared to class I alleles, class III VNTR alleles were 
associated with 2- to 3-fold higher INS mRNA levels (Pugliese et al. 1997; Vafiadis et al. 
1997). The higher levels of class III thymic INS expression may promote immune 
tolerance and thus protect against TlD. Mapping of polymorphisms in IDDM2 suggest 
that INS VNTR is the underlying causative variant for TlDwith association of other 
markers to TlD explained by LD (Barratt & Todd, unpublished; Bennett et al. 1997; 
Undlien et al. 1995). Estimates from large datasets suggest that the susceptible alleles 
predisposes to TlD with an odds ratio of 2.0 (Barratt & Todd, unpublished). 
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1.3.3 CTLA-4 
The Cytotoxic T Lymphocyte-Associated 4 (CTLA4) protein is a costimulatory molecule 
that is important in determining T-lymphocyte immune responses (Egen et al. 2002). 
Polymorphisms in the CTLA-4 gene has been associated with a number of human 
autoimmune disorders including Grave's disease, TlD, autoimmune hypothyroidism and 
multiple sclerosis (Kristiansen et al. 2000). The CTLA-4 orthologue in mouse maps to a 
disease locus in NOD (Hill et al. 2000; Ueda et al. 2003). The fine mapping of the CTLA-4 
region confined human Grave's disease to CLTA-4 itself from its flanking genes (Ueda et 
al. 2003), with drop offs in disease association corresponding to with falls in LD. Analyses 
in 3,671 families confirmed CLTA-4 association in TlD, but with overall odds ratio of only 
1.07 (Ueda et al. 2003). The study of CTLA-4 has, therefore, been interesting in many 
ways. Firstly, the same genetic factors can contribute to different but related diseases, and 
this concept helps in the selection of candidate genes. Secondly, knowledge of LD can 
assist in the fine mapping of disease variants, although it may be both region and variant 
dependent. Finally, the effects of disease variants can be very weak, and will be difficult 
to detect without large sample sizes. 
1.3.4 Genomewide linkage studies 
The first two genomewide linkage scans for TlD involved 94 and 61 ASPs (Davies et al. 
1994; Hashimoto et al. 1994). Both studies had> 90% power for detecting loci with As~ 3 
and demonstrated significant linkage at MHC but their agreement on positive findings was 
otherwise poor. The suggestion of low statistical power prompted second-generation 
genome scans with larger sample sizes. Mein et al. (1998) used 356 UK ASP (included 94 
from Davies et al. (1994)) and noted linkage in IDDMJ, IDDM2 and on chromosome 
lOcen (IDDMJO). By conditioning for IDDMJ or IDDM2, a further 15 loci showed some 
evidence of linkage with MLS > 1.5. Concannon et al. (1998) performed a USA based 
genome scan with 212 ASPs and followed up findings with P < 0.05 with an additional 
467 ASPs. They noted significant linkage at IDDMJ and chromosome lq. Six additional 
loci showed MLS greater than 1.0. However, confirmation of previous positive findings 
was once again poor. 
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Recently, a genome scan consisting of 225 multiplex families together with the subjects 
from Concannon et al. (1998) and Mein et al. (1998) totally 831 ASPs was conducted (Cox 
et al. 2001). It had 90% power to detect linkage for loci with As= 1.3 at significance 
threshold of a= 7.4 x 10-5• Three regions showed significant linkage (P < 2.2 x 10-5): 
6p21 (IDDMJ), llp15 (JDDM2), and 16q22-q24; and, four more showed suggestive 
evidence of linkage (P < 7.4 10'4): lOpll (IDDMJO), 2q31 (IDDM7, IDDM12, and 
IDDM13), 6q21 (IDDM15), and lq42. Another recent study consisting of 464 
Scandinavian ASPs showed significant linkage at IDDMJ and IDDM15 and suggestive 
linkage from loci on chromosomes 20, 5q and 16p (European Consortium for IDDM 
Genome Studies 2001). 
1.4 Aims 
This thesis aims to evaluate some issues relating to the detection TlD associated variants. 
Similar principles may apply to the study of other common multifactorial diseases. More 
specifically: 
1. Assessment of feasibility of association mapping in linked regions, taking into 
consideration the potential for multiple rare variants, gene-gene and gene-
environment interactions; 
2. Evaluation of SNP density requirements for large-scale indirect association studies 
through simulated sampling of real data; and, 
3. Identification of TlD associated variants in candidate gene/region laboratory 
studies. 
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Chapter 2 Association Mapping in Linked Regions 
2.1 Background 
Linkage mapping followed by association analysis in the most disease-linked region is 
currently a major strategy for genetic analysis of common multifactorial diseases 
(Altmuller et al. 2001; Hugot et al. 2001; Todd 2001). This two-staged approach was first 
used to position clone rare Mendelian disorders (Rommens et al. 1989), and is beginning to 
bear fruit for complex diseases (Horikawa et al. 2000; Hugot et al. 2001; Ogura et al. 2001; 
Walley et al. 2001). Initial linkage studies provide information on both the position and 
the genetic effect of the underlying disease loci. Given current technology and costs, 
studying a specific linked region is more technically and financially feasible than whole 
genome association analysis (Risch and Merikangas 1996). 
Implicit in adopting the two-staged approach is the assumption that genetic variants 
contributing to linkage are detectable by association. This idea is somewhat intuitive given 
the knowledge that association studies are more powerful than linkage studies (Spielman et 
al. 1993; Copeman et al. 1995; Risch and Merikangas 1996; McGinnis 2000). However, 
linkage may be due to multiple genetic variants (Hugot et al. 2001; Ogura et al. 2001) and 
the population used for association may not be the same as those used for linkage. It is 
also unclear what the role of rare alleles is in common diseases (Pritchard 2001). 
Furthermore, the selection of positively linked regions from genomewide scans are likely 
to provide upward biases in the estimation of locus-specific effects with the true effect 
sizes being much less (Beavis 1994; Goring et al. 2001). 
The relationship between measures of genetic linkage and association is hereby re-
exarnined. Previous studies on this topic compared the sample size requirements to 
achieve significant linkage and association for a given set of genetic risk parameters (Risch 
and Merikangas 1996; Knapp 1999; Rybicki and Elston 2000). However, for association 
mapping in a linked region, we are interested in the feasibility of association mapping 
provided that linkage can be established. My findings here suggest that if positive linkage 
finding can be confirmed in a genomic region spanning 30 cM of a chromosome, then it is 
likely to have sufficient genetic effects to allow systematic association mapping with 
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surprisingly small sample sizes required for even rare alleles with small linkage effect. My 
results provide justification for the expense and considerations necessary in collecting 
multiplex families for linkage versus case-control designs with much greater genotyping 
expenditure. 
2.2 Methods 
2.2.1 Estimation of genetic effects 
For association mapping in linked regions, the underlying genetic effects may be estimated 
from the initial linkage studies. The genetic effects detected by linkage are commonly 
measured by the sibling recurrence risk, As, and that of association are measured by the 
transmission ratio (i') of the transmission disequilibrium test (TDT) or genotype relative 
risk (ORR)(Spielman et al. 1993; Risch and Merikangas 1996). Relationships between 
these measures are dependent on the disease model of inheritance and allelic frequencies 
(Rybicki and Elston 2000). Examination of the relationship between these measures in the 
past, have started with ORRs and allelic frequencies leading to As. However, in practice 
linkage analyses provide estimates for As so the reverse conversion is more useful. The 
relationship between these variables under the assumptions that there exists only one 
disease variant in a linked region and that there are no gene-environment interactions is 
first investigated. 
For the general genetic model with (fo, f1, f2) the disease penetrances of the genotypes (AA, 
Aa, aa) of a diallelic marker, it could be shown algebraically that ORR1 = fi / f0 and ORR2 
= f2 / f0 are sufficient to provide a unique As for a given allele frequency. As is defined as 
the relative disease risk of the sibling of an affected individual relative to that of the 
general population. The different single-locus genetic models investigated and their 
penetraces in terms of ORR related parameters, ~ and y, are: 
multiplicative, (fo, f1, f2) = f0 x (1, y, y2); 
additive, (fo, f1, f2) = f0 x (1, 1 + ~' 1 + 2~); 
dominant, 
recessive, 
(fo, f1, f2) =fox (1, ~' ~); and 
(fo, f1, f2) =fox (1, 1, ~). 
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The transmission ratio, 't, is the probability that an affected offspring would receive a 
particular marker allele from a heterozygote parent. It has a null value of 0.5 . Given the 
multiplicative model for the effects of alleles, GRR1 = y and GRR2 = y2, 't = y I (l + y) 
(Risch and Merikangas 1996). 't can also be calculated for other disease models using 
formulae of McGinnis (2000). 
The values of 't and GRR for given As are estimated by solving the equation: 
As= 1 + (Y2 VA+ 114 Vo) / K2 
VA and Vo are the additive and dominance variances respectively, and K is the population 
prevalence of the disease (James 1971; Risch 1990). These parameters can be expressed in 
terms of the disease allele frequencies, p, and the penetrances of disease genotypes 
(Kempthome 1957; James 1971): 
K = p2 fo + 2 pq ft + q2 f 2 
VA= 2 pq (p (f1 - fo) + q (f2 - f1))2 
Vo = p2q2 (f2 - 2f 1 + fo/ where q = 1 - p 
Using formulae above, GRRs were estimated for different values of As, disease allele 
frequencies, and genetic models. This was done using both the Newtonian method of 
equation solving and also by the method of approximation and halving (Ortega and 
Grimshaw 1999). Computer programs were written in C. 
2.2.2 Sample size calculations 
Sample size requirements for the TDT are calculated using the first approximation method 
of Knapp (1999) for singleton families. A significance threshold was chosen based on 
conservative assumptions. Assuming that there are up to 5Q,OOO genes in the human 
genome (latest estimates on the number of human genes is around 25,000), each linkage 
region is -30 cM (or 1 % of the genome), and 100 independent tests for markers of di-
allelic nature are required per gene (equivalent to almost three tests per kb for the average 
35 kb gene (Deloukas et al. 2001)), then 50,000 tests are needed for association mapping in 
a linked region. To obtain an overall type I error rate of 5%, a significance threshold a = 1 
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x 10-6 would be required for each individual test. Given LD between closely located 
markers, it is unlikely that there would be as many as three independent tests per kb, 
therefore the significance threshold here is probably conservative. 
2.2.3 Two loci models 
The assumption a single disease variant in the linked region is now relaxed. Four two-loci 
models were investigated assuming disease alleles of equal frequency and penetrance. 
Define fij as the penetrance of the genotype gij consisting of i and j disease alleles from the 
first and second di-allelic locus respectively. Conversions of two-loci penetrances to As 
were done by calculating genetic variances from genotype risks (Tiwari and Elston 1998) 
and then converting that to As (Cordell et al. 2000). 
Model I - multiplicative model: fij = foo x y i +j, with As dependent yon and disease allele 
frequency. 
Model II - additive model: the penetrance of genotype gij is fij = foo + (i + j) x ~' with As 
dependent on~ and disease allele frequency. 
Model III - positive epistasis model: both loci contribute at least one disease allele for there 
to be an increased risk of disease. The penetrance matrix is 
!02} {1 1 1} f12 = foo X 1 Y Y 
!22 1 r r 
Model IV - negative epistasis model: haplotypes contributing to disease susceptibility such 
that for two di-allelic disease variants A and B, the disease causing haplotypes are A1B2 
and A2B 1, and A lB 1 and A2B2 are protective. Epistasis of this type could occur for 
variants involved in gene regulation and protein structures. The penetrance matrix is 
{
foo 
!10 
!20 
!02} { 1 f12 = foo X ,: 
!22 r 
22 
r 
r2 
r 
2.2.4 Three or more loci models 
Conversions of GRR to As for additive and multiplicative models for three loci in the 
linked region were implemented by combining the methods of Cordell et al. (2000) and 
Tiwari and Elston (1998). Results for multiple loci of an additive model can be obtained 
from single locus model, because in this case there are no epistatic variances. Using the 
multiple-loci relationship between As and variance components described by Cordell et al. 
(2000), I derived the following simple formula: 
As - 1 = (A.d - 1) + (A,.2 - 1) + ... + (Ask - 1) 
where Ask is the theoretical As for the k-th disease variant that depends on given allele 
frequencies and GRRs. 
2.2.5 Gene environment interaction 
The total As can be divided into three components: genetic, environmental, and genetic and 
environmental interactions (Guo 2002), as is with inheritance in general (Fisher 1918). For 
our analysis of association mapping in linked regions, pure environmental components of 
As are not considered, as they do not contribute to chromosome linkage. For the one-locus 
model, the penetrance of the genotype gi, consisting of i disease alleles, is fi = f(gi , E) 
where E is the environmental variable. The following scenarios are considered: 
Scenario I 
In the simplest scenario, the population used for association analyses is the same as, or 
similar to, that used for linkage analyses. This can happen with careful sampling of closely 
related populations and is certainly achieved when the same affected sib-pair (ASP) 
families are used for both studies. In this scenario, the penetrances of the genotypes for 
linkage and association studies are the same. Hence the relationship between As, 't and 
GRR are conserved regardless of the gene-environment interactions. 
Scenario II 
In this scenario, the populations used for linkage and association studies are exposed to 
different environmental risk factors but GRRs are constant. An example of this scenario 
would be when there exist constant linear relationships between deleterious environmental 
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exposure and disease penetrances for all genotypes, and the disease is absent when the 
environmental exposure is absent. Hence the penetrances are f0 = k0 x E, f 1 = k1 x E, and fi 
= k2 x E, for constants k0 , k1, and kz. Thus GRR 1 = k1 / ko and GRR2 = k2 / ko are 
independent of the level of environmental exposure. 
For scenario II the relationship between As, 't and GRR are conserved between different 
populations. This happens in spite of differences in genotypic penetrances and disease 
prevalence between populations. 
Scenario ill 
This scenario assumes that GRRs are not the same in the populations used for linkage and 
association studies. Scenarios of this type can occur due to different genetic or 
environmental backgrounds affecting the penetrances of the genotypes of interest and may 
be the result of differing sampling geography or ascertainment method. Under a 
multiplicative model for effects of alleles, the penetrance for the genotype gi is fi = f0 x V, 
hence the multiplicative effect of an allele is y. Let YL and YA be they values for linkage 
and association studies respectively and let 11 be the coefficient of GRR differences such 
that YA = YL 11 • Sample size requirements for As = 1.1 for different values of 11 are calculated. 
2.3 Results 
Figure 2.1 shows that for a given value of As, there is a U-shaped relationship between the 
association measurements and disease allelic frequency, assuming a multiplicative model 
for the effects of alleles. This occurs with the minimum values of 't and GRR 
corresponding to disease allele frequencies of between 0.2 and 0.5. I noted that the 
minimum values of 't and GRR are not small, even for very small values of As, For 
example, when As= 1.05, the minimum 't and GRR under a multiplicative genetic model 
are 0.61 and 1.55, respectively. Similar U-shaped relationships between disease allele 
frequency and measurements of association exist for the additive, dominant and recessive 
models. 
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Figure 2.2 shows the sample size requirements in trio families (two parents and an affected 
offspring) for association studies in linked regions under different single-locus genetic 
models. For the same As, higher values of 't and ORR are expected for rare alleles 
compared to common ones (Figure 2.1), so the problems of low statistical power with rare 
alleles are partly compensated for by the proportionally larger genetic effects. For loci 
with As= 1.15 and disease allele frequencies= 5%, 379 trios provide sufficient power for 
association under a multiplicative genetic model. Even for As= 1.05, 1,289 trios would be 
sufficient for mapping genes with disease allele frequency of 1 %. 
Figure 2.3 shows the sample size requirements for the different two-loci models. Under 
the multiplicative model, 1,324 trios would be sufficient to detect association for two equal 
and tightly linked but otherwise independent disease variants of 1 % frequency given 
linkage with As= 1.1 (Figure 2.3A). If three such disease variants were assumed then 1821 
trios would be required. Similar results exist for the additive model (Figure 2.3B). For the 
positive epistatic model, rare disease variants would be difficult to detect since both loci 
must contribute at least one disease allele each (Figure 2.3C). The opposite is true for the 
negative epistatic model (Figure 2.3D) where the presence of common variants cancel out 
the effect of each other. 
A comparison of sample size requirements for a fixed As versus a fixed ORR in a single 
locus multiplicative model is shown in Figure 2.4. 
Sample size requirements are strongly affected by gene-environment interaction and 
population differences (Figure 2.5). Sample size requirements are more than tripled when 
11 is reduced by a half for disease allele frequencies less than 0.5. The effects are even 
stronger when disease allele frequencies are less than 0.1. 
2.4 Discussion 
The relationship between ORR, 't, and disease allele frequency under constant As values 
have been examined. Studies of these variables in the past have demonstrated the 
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increased power of association analyses over linkage analyses (Risch and Merikangas 
1996; Knapp 1999). The results here show that if reproducible evidence for linkage could 
be obtained, then the underlying disease variants would correspond to large values of ORR 
and 't. Even though publication bias is possible, practical association mapping studies of 
linked regions have found surprisingly strong levels of association in regions of positive 
linkage supporting our theoretical findings (Hugot et al. 2001; Ogura et al. 2001). A 
caveat to these results is genetic epistasis. Figures 2.3C and 2.3D show that, depending on 
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the model, sample size requirements for rare and common disease alleles could both be 
affected significantly. Furthermore, epistatic models have been reported in which no 
single locus association could be shown despite joint contribution to linkage (Wilson 2001; 
Culverhouse et al. 2002)), but these models may be unrealistic in biological scenarios. 
It is likely that positive linkage findings from genomewide studies would report 
overestimation of the magnitude of underlying genetic effects, which is commonly the case 
with genetic studies in which thresholds are pre-set (Beavis 1994; Goring et al. 2001; 
Ioannidis et al. 2001; Hirschhorn et al. 2002). The finding here that association mapping is 
possible even with loci of very small As suggests that fine mapping of loci detected by 
linkage should be achievable with moderate sample sizes, even given overestimation of As, 
Furthermore, the assumptions were conservative in two ways. First, 100 tests per gene was 
assumed leading to a= 10-6. Calculations repeated using a= 10-5 result in approximately 
25% reduction in sample size requirements. Second, calculations were based on TDT for 
singleton families. Association studies using more than one affected offspring per family 
may have significantly smaller sample size requirements for detecting association in the 
presence of linkage (Risch 2000). An efficient strategy is to use the same affected sib-pair 
(ASP) families for both linkage and association, which has the added benefit of 
overcoming the problems of population differences and disease heterogeneity. It is noted 
that case-control analyses are potentially even more powerful than family-based 
association analyses especially with the use of hyper-normal controls (Morton and Collins 
1998), and, in some cases, if cases have a family history of the disease (Morris et al. 1997; 
Wright et al. 1999). Cases and controls are also easier to ascertain especially for late onset 
diseases. Sample size requirements are much larger for variants of less than 0.25 in 
frequency in the recessive model (Figure 2.2D). However, it is unlikely that such loci with 
low As would be det~ctable by linkage because sample size requirements under the 
recessive model for low As are extremely large. 
Population differences and gene-environment interactions can significantly alter the 
sample size requirements for association mapping (Figure 2.5). This will not be a problem 
for investigators following up their own linkage signals for association Using the same 
study population. However, if different populations are used then the establishment and 
replication of positive association (and linkage) findings may be compromised. 
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Owing to the relationship between genetic measures of association and linkage, disease 
variants causing strong association may contribute little to linkage (Figure 2.1 and Rybicki 
and Elston (2000)). This in part explains the failure of published linkage studies because 
the number of ASP families are usually in the vicinity of 200, with few studies having 
more than 500 ASPs (Altmuller et al. 2001). A linkage study with 500 ASPs has 95% 
power to detect significant linkage for loci with As :2: 1.6, but only 10% power for loci with 
As = 1.2 (McGinnis 2000). In the example of TlD, multiple genome scans suggest that 
there exists only one locus with As :2: 1.6, i.e. filAIIDDMl (Cox et al. 2001; European 
Consortium for IDDM Genome Studies 2001), and the two non-filA genes so far 
implicated in the disease by association analyses have calculated As values less than 1.1 
(Lucassen et al. 1993; Nistico et al. 1996; Ueda et al. 2003). For example, the insulin gene 
(INS), is associated with TlD with a allelic odds ratio of 2.0 (Barratt, B and Todd, J 
unpublished), and this is equivalent to a calculated As of only 1.07. A As of 1.1 would 
require more than 3,500 ASP families to provide 80% power for suggestive linkage (P < 
7.4 x 10-4)(Lander and Kruglyak 1995). So far, linkage studies have used only a few 
hundreds of families and it is now evident that for most disease loci thousands are required 
(Caulfield et al. 2003). Linkage studies with large numbers of families (>4,000) may be 
possible with the formation of large international consortium for family collectors. The 
linkage approach will also provide protection against severe epistasis for which association 
studies may be underpowered (Wilson 2001; Culverhouse et al. 2002). Furthermore, it will 
provide a positive signal even if multiple rare disease variants are present in a locus, a 
situation that could be problematic for LD or indirect association mapping. 
The two staged linkage based approach, however, may soon become eclipsed by direct and 
indirect whole genome association analyses. It is likely that within the next five years, the 
ingredients for genome wide association studies such as cheap high throughput genotyping 
technologies, and genomewide polymorphism and haplotype maps (International HapMap 
Consortium 2003), will become available. In common diseases, the smaller requirements 
for association studies and its ability to locate disease variants to within a small genomic 
region, make association analyses more attractive. It has the further advantage that there 
likely exist many more loci with mild to moderate risks detectable by association than 
those major loci detectable by linkage (as discussed in Chapter 1), making the approach 
more rewarding. In Chapter 3, I suggest that -500,000 htSNPs may be suffice for an initial 
31 
-- ------------
genome scan for association. Using 1,000 cases and 1,000 controls results in 1012 
genotypes with a cost a total of $10 million if technologies will eventually allow $0.01 per 
genotype. This cost should be weighed against the expenses involved in ascertaining large 
number multiplex families required for linkage. 
It has been shown here that reliable association studies in linked regions are possible with 
achievable sample sizes, even with rare disease alleles and inflation of As estimates, 
provided gene-gene and gene-environment interactions are negligible. Consequently, I 
suggest that in the two-stage gene mapping approach of linkage followed by association 
analyses, power and sample size considerations are far more problematic for the linkage 
stage then for the association stage. Furthermore, in the association mapping stage, for the 
initial detection of association weak underlying genetic effects may be of less concern than 
other problems such as sampling bias, laboratory errors (especially for rare alleles), 
insufficient knowledge of haplotype structures and epistasis (Gordon et al. 2001; Johnson 
et al. 2001; Culverhouse et al. 2002; Gabriel et al. 2002). 
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Chapter 3 SNP Density Requirement for LD Mapping 
3.1 Background 
Indirect genetic association mapping aims to detect causative disease variants via LD with 
genotyped SNPs (Collins et al. 1997; Botstein and Risch 2003). This approach is currently 
targeted at common SNPs, as they make at least some contribution to human diseases 
(Lohmueller et al. 2003) and allow for greater statistically power than is available for rarer 
variants. It is unclear, however, what proportion of the estimated six million common 
(frequency 2: 10%) European SNPs in the human genome (Kruglyak and Nickerson 2001; 
Carlson et al. 2003) need to be first discovered and validated to ensure highly 
comprehensive large-scale association mapping. The construction of SNP maps allows LD 
analyses and selection of an economic and statistically powerful set of haplotype tag SNPs 
(htSNPs) for genotyping in association studies (Johnson et al. 2001; Meng et al. 2003). 
The construction of genome-wide haplotype maps in multiple populations is in progress 
with the International HapMap Project (International HapMap Consortium 2003). 
The issue of SNP density requirement for successful LD mapping is essential to the 
construction of SNP maps (International HapMap Consortium 2003). Previous estimates 
on the density requirements have been based on relatively sparse sampling of the SNP 
content of the genome (Gabriel et al. 2002; Clark et al. 2003; Shifman et al. 2003). 
Estimates from practical studies, and from theoretical models, have suggested that, for 
successful indirect LD mapping, the SNP map density may need to be quite high, perhaps 
at greater than one SNP per 3 kb (Kruglyak 1999; Martin et al. 2000; Ardlie et al. 2002). 
Recently, Carlson et al. (2003) provided SNP data from 50 completely resequenced genes 
allowing a more accurate assessment of SNP ascertainment. They estimated that from the 
2.7 million unique SNPs then available in dbSNP (Smigielski et al. 2000), approximately 
1.35 million were common in Europeans, and genotyping of these common SNPs would 
ascertain 77% of all common European SNPs at r2 2: 0.8. Since the number of disease-
associated variants in the genome is likely to be large, such rates of SNP ascertainment 
would be of significant value to genetic researchers. However, owing to variations in LD 
and in SNP sampling, incomplete maps will inevitably contain regions with very poor SNP 
capture, and this has not been previously investigated. Accounting for LD and sampling 
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variations, I estimated the SNP coverage in genes for different map densities via simulated 
sampling from the near complete SNP maps of the UW-FHCRC Variation Discovery 
Resource database (SeattleSNPs, http: //pga.mbt.washington.edu/). 
3.2 Methods 
3.2.1 Calculation of LD statistics 
The indirect ascertainment of unobserved SNPs was calculated using the pair-wise LD 
measurement r2, calculated via the method of Hill (1974). This LD statistic is inversely 
related to the required sample size for association mapping, given a fixed genetic effect 
(Sham et al. 2000; Pritchard and Przeworski 2001). An unobserved SNP was regarded as 
captured by an observed one, if their pair-wise r2 reached the threshold of interest. It was 
decided to focus on SNP ascertainment instead of LD statistics per se as the former is more 
directly informative for studying disease association. All sampling and calculations were 
performed using programs written in C. 
3.2.2 Evaluation of? biases in 23 individuals 
Since in the SeattleSNPs database only 23 European-derived individuals DNA samples 
from were harvested for SNPs, it was necessary to check that the use of r2 to estimate SNP 
coverage would be robust and not biased due to sampling error. In theory, data from a 
small number of individuals lead to inflation of observed r2 values. Using results from a 
neutral coalescence model, Carlson et al. (2003) suggested that r2 values from 23 
individuals are useful. This issue was re-examined using actual genotype data of six SNP 
rich genomic regions made available by colleagues in the Diabetes and Inflammation 
Laboratory. 
Sources of r2 bias 
To examine the likely sources of r2 bias, for each SNP pair, 10,000 successful samples 
were obtained consisting of 23 individuals each. Successful samples had observed rare 
allele frequencies of both SNPs ~ 0.1. True allele frequencies and true r2 were those 
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estimated from the maximum number of individuals for each genomic region. Bias= 
(observed r2) - (true r2). 
Distribution of true and observed r2 in genotype data 
The six genomic regions were sampled to examine the distributions of real and observed 
r2. For each simulation, two SNPs and 23 individuals were randomly selected. A sample 
was successful and its results recorded if and only if both markers had observed allele 
frequencies 2'.: 0.1. For each successful sample, real and observed r2 were calculated. One 
hundred thousand (100,000) successful samples were taken for each genomic region. 
3.2.3 Dataset for assessment of SNP density requirement 
Data used for the estimation SNP density requirement for LD mapping was derived from 
the SeattleSNPs database as of June 1, 2003. Of the 121 genes then available, 73 
autosomal gene segments that were greater than 10 kb in length and more than 90% 
resequenced were chosen. SNP genotypes were of 23 European American individuals. 
3.2.4 Marker sampling simulations 
From the set of all SNPs derived from SeattleSNPs, subsets of mapped (observed) SNPs by 
sampling based on density were created. For each set of simulations a pre-determined 
target marker density was set (e.g. one SNP per 5 kb). The number of markers sampled 
was the minimum number of markers required to achieve the target density. If a gene 
segment was less polymorphic than a target density, then all SNPs in that segment were 
selected. 
To understand how different sampling approaches may affect the final outcome, three 
sampling strategies were devised: (i) random sampling from the pool of all genes, (ii) 
random sampling within each gene to a given density, and (iii) sampling with the aim of 
even spacing by choosing each SNP to be as close to a pre-set evenly spaced position as 
possible. Ten thousand sampling trials were taken for the random sampling methods for 
each target density. 
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3.2.5 htSNP selection 
For each gene, starting from the set of all mapped SNPs, SNPs were minimized to retain 
only one variant from each pair with ? 2: 0.8. This was performed using a backward 
selection procedure with the gradual elimination of SNPs. 
3.3 Results 
3.3.1 Evaluation of? bias for 23 individuals 
Data from six genomic regions available from the Diabetes and Inflammation Laboratory 
are shown in Table 3.1. 
Figure 3.1 shows the bias of observed r2 as a function of underlying allele frequencies and 
real?. It shows that SNPs with true rare allele frequencies< 10% were more likely to 
result in biased r2 values. Since only SNPs observed with MAF of great than 10% would 
have their results recorded, this suggests that for alleles with true MAF < 10%, upward 
biases in allele frequencies resulted in upward biases in?. Biases are also more prominent 
for SNP pairs with lower true r2 values. 
Table 3.1 Characteristics of six genomic regions used to assess 
the reliability of estimated r2 from sampling 23 individuals. 
Region SNPs Unrelated Individuals Size (bp) 
ChrlO 44 944 30,198 
CTLA-4 34 672 24,191 
LRP5 30 182 59,982 
INS &TH 31 742 29,745 
MRCl 28 944 87,627 
VDR 46 936 106,200 
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Figure 3.2 shows the overall distribution of true and observed r2. In general there were 
upward biases of observed r2 values. These were less prominent for r2 2: 0.5. It is 
important to note that upward biases in observed r2 lead to overestimated SNP coverage 
and thus underestimated SNP density requirement for LD maps, making the conclusion on 
SNP map density conservative. 
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Figure 3.3A shows the proportion of SNPs with observed r2 above a cut-off has the real r2 
above that cut-off. Figure 3.3B shows the proportion of SNPs with r2 observed above a 
cut-off has the real r2 above the cut-off minus 0.1 (eg. if observed r2 is above 0.8, what 
proportion of r2 are above 0.7?). These suggest that the use of pair-wise LD as a method 
of selecting htSNPs may be reliable. 
3.3.2 Dataset for assessment of SNP density requirement 
Seventy-three gene segments from SeattleSNPs satisfied the selection criteria (Table 3.2). 
This yielded of 2,523 common European SNPs and 1,586 kb in genomic length. 
3.3.3 SNP coverage 
Based on simulated sampling of 73 gene regions, Figure 3.4 shows the proportion of 
overall SNPs ascertained directly or indirectly as functions of target SNP densities . 
Sampling one common SNP (frequency~ 10%) per 5 kb (0.2 SNPs per kb in the figures) 
would capture more than 50% of SNPs at r2 ~ 0.8, and greater than 80% of SNPs in 22 
genes (30%) in an evenly spaced map (Figure 3.5A). Sampling one SNP per 2.5 kb 
ascertained 76% of SNPs, concurring with the previous estimate for the SNPs in dbSNP 
(Carlson et al. 2003), and provided more than 80% SNP coverage for 38 of the 73 genes 
(52%, Figure 3.5B). However, owing to variation in LD between different genomic 
regions, to achieve comprehensive disease mapping for common variants is more difficult. 
In the evenly spaced sampling of one SNP per 2.5 kb, seven genes (10%) were less than 
50% covered. To obtain 80% coverage of SNPs in 80% of genes, sampling at densities of 
greater than one SNP per 1.5 kb was required in -10% of genomic regions (Figure 3.5C). 
Random sampling yielded lower levels of SNP capture in genes than the evenly spaced 
method. 
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Table 3.2 Dataset used for map density sampling 
.Gene SNPs Length Gene SNPs Length 
MAF ~ 10% MAF ~ 10% 
ABO 150 23,759 KLKB1 89 33,504 
BDKRBZ 22 15,152 KNG 116 29,388 
CCR2 19 10,073 MAP3K8 36 31,602 
CD36 35 30,180 MMP:f 23 13,003 
CRF' 15 10,451 MMP9 18 11,224 
CSF3R 23 18,843 NOS3 34 25,106 
DCN 6 35,378 PLAT 35 36,269 
EPHB6 5 19,655 PLALI 15 10,075 
F10* 32 24,589 PLAUR 35 25,423 
F11 42 27,035 PON1 60 29,370 
F12 12 10,616 PON2 73 32,705 
F2 21 22,128 PROC' 28 13,870 
F2ft 28 24,771 PROS1* 9 31,612 
F2RL1u 24 18,351 SELE 33 14,019 
F3 19 17,222 SELL 55 24,822 
FGBu 27 11,956 SERP/NC1u 14 16,330 
FGGu 7 10,168 SERPINE1u 31 14,544 
ICAM1 19 19,022 SFTPA1 39 24,037 
IL10RA 16 19,942 SFTPA2 25 18,039 
IL12Au 23 11,792 SFTPaH 10 11,807 
IL12B 23 15,648 SFTPD 55 23,538 
IL 15RA 75 35,809 SMP1u 15 25,269 
IL1~ 8 10,998 STAT4* 12 10,545 
IL1A 45 18,446 STAT~ 12 18,891 
IL1B 17 17,447 TF 76 37,308 
IL1R1 45 27,864 TFPI 44 38,945 
/L1R2 80 23,160 TGFB3 24 23,990 
IL1RN 69 19,677 TIRAP 40 20,684 
IL21ft 37 26,391 TNFAIP1u 5 15,259 
IL24u 13 11,114 TNFAIP2 19 15,768 
IL2RB 59 26,469 TNFAIP3 15 19,810 
/L4u 32 22,845 TNFRSF1A 14 17,350 
!L4ft 58 26,550 TRAF6 23 26,556 
IRAK4 10 33,033 TRPVS 9 29,923 
ITGA2* 157 52,149 VCAM1 22 22,868 
JAK3* 32 18,424 VEGF' 28 15,442 
KLK1 27 10,094 
ALL 2,523 1,586,096 
* Only one part of each gene satisfying selection criterion was chosen. 
# Twenty-two genes overlapped with those used by Carlson et al. (2003). Differences in data sets were due to 
my selection of only gene segments longer than 10 kb to minimize sampling variation, my allowance of 90% 
complete segments, and that there were 31 more genes in SeattleSNPs since their primary publication. 
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MAF :2:: 10% MAF :2:: 10% 
ABO 150 23,759 KLKB1 89 33,504 
BDKRBZ 22 . 15,152 KNG 116 29,388 
CCR2 19 10,073 MAP3KB 36 31,602 
CD36 35 30,180 MMP:! 23 13,003 
CRP 15 10,451 MMP9 18 11,224 
CSF3R 23 18,843 NOS3 34 25,106 
DCN 6 35,378 PLAT 35 36,269 
EPHB6 5 19,655 PLAil 15 10,075 
F10* 32 24,589 PLAUR 35 25,423 
F11 42 27,035 PON1 60 29,370 
F12 12 10,616 PON2 73 32,705 
F2 21 22,128 PROcf 28 13,870 
F2ft 28 24,771 PROS1* 9 31 ,612 
F2RL1# 24 18,351 SELE 33 14,019 
F3 19 17,222 SELL 55 24,822 
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ICAM1 19 19,022 SFTPA1 39 24,037 
IL 10RA 16 19,942 SFTPA2 25 18,039 
IL 12A# 23 11,792 SFTPaH 10 11,807 
IL12B 23 15,648 SFTPD 55 23,538 
/L 15RA 75 35,809 SMP1# 15 25,269 
/L 1if 8 10,998 STAT4 * 12 10,545 
IL1A 45 18,446 STAT~ 12 18,891 
IL1B 17 17,447 TF 76 37,308 
IL1R1 45 27,864 TFPI 44 38,945 
IL1R2 80 23,160 TGFB3 24 23,990 
/L1RN 69 19,677 TIRAP 40 20,684 
IL21Ft 37 26,391 TNFAIP1# 5 15,259 
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IL2RB 59 26,469 TNFAIP3 15 19,810 
IL4# 32 22,845 TNFRSF1A 14 17,350 
IL4R# 58 26,550 TRAF6 23 26,556 
IRAK4 10 33,033 TRPV5 9 29,923 
ITGA2 * 157 52,149 VCAM1 22 22,868 
JAK3* 32 18,424 VEGP 28 15,442 
KLK1 27 10,094 
ALL 2,523 1,586,096 
* Only one part of each gene satisfying selection criterion was chosen. 
# Twenty-two genes overlapped with those used by Carlson et al. (2003) . Differences in data sets were due to 
my selection of only gene segments longer than 10 kb to minimize sampling variation, my allowance of 90% 
complete segments, and that there were 31 more genes in SeattleSNPs since their primary publication. 
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Figure 4.2 Variation of SNP capture between genes for different marker densities . Marker densities of one SNP per 5 kb (A), 2.5 kb (B), 1.5 kb (C) and one kb (D) are 
shown. For each sampling methods, random overall (filled bars), random within genes (patterned bars) or evenly spaced (unfilled bars), the 73 genes studied were divided 
into ten bins based on the rates of SNP ascertainment at the marker density. 
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3.3.4 Number of htSNPs 
The issue of number of htSNPs was next examined. For each gene, starting from all 
mapped common SNPs, SNPs were minimized to retain only one variant from each pair 
with r2 2: 0.8. The resultant htSNPs should have similar rates of ascertainment of 
unobserved SNPs as the set of mapped SNPs. Using evenly spaced SNP maps, 366 and 
483 htSNPs were chosen for initial SNP map densities of one SNP per 2.5 kb and one SNP 
per 1.5 kb, respectively (43% and 53% reduced genotyping). If these results are extended 
to the entire genome, then 760,000 and 1.0 million SNPs would be assayed for association 
studies based on the respective SNP maps. For the complete SNP map based on these 73 
genes, 695 htSNPs were chosen equating to 72% reduced genotyping, translating to 1.4 
million htSNPs genomewide. 
3.4 Discussion 
The usefulness of different density SNP maps has been estimated and variability between 
genomic regions has been shown. The varied SNP density requirements in different parts 
of the genome is consistent with previous observations of LD and SNP density variations 
(Patil et al. 2001). For genome-wide SNP map construction by ascertaining SNPs 
randomly from a relatively small number of individuals, sampling errors will also be 
important. The current HapMap proposal of one SNP per 5 kb map (International HapMap 
Consortium 2003) will be able to delimit the majority of LD blocks (Chapter 1), but not 
sufficient to resolve haplotype structures. The uncertainty regarding the actual number of 
SNPs and haplotypes in any particular region will make hierarchical SNP sampling 
strategies challenging, since the observed haplotype structure is a function of both the 
underlying haplotypes and chance sampling. Nevertheless, the latest build (118) of dbSNP 
has 5.8 million unique SNPs and will be of a better resource to begin SNP map 
construction than the 2.7 million SNPs previously available (Carlson et al. 2003). It seems 
likely that even in Europeans, many more than 2.7 million SNPs will need to be genotyped 
in the mapping panel to achieve good ascertainment for a large proportion of genes. 
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A number of factors could lead to differences in SNP map density estimates. Indirect 
testing of unobserved variants using haplotypes, and not simply via pair-wise r2 as it is 
done here, should lower the map density requirements. However, increased potential 
search space and degrees of freedom in haplotype based tests may affect statistical power 
for detecting disease association (Chapman et al. 2003). The study of lower frequency 
SNPs and of African populations will also require denser maps (Gabriel et al. 2002; 
Carlson et al. 2003). In contrast, regions of strong LD with limited haplotype diversity 
would provide better SNP coverage for the same density and lower htSNP requirements. 
When I performed simulations using a coalescent model (Hudson 2002), with nucleotide 
diversity of 7.5 x 10-4 per bp (for genes in SeattleSNP), I found that studying 100 kb 
genomic segments provides better overall coverage than those of our size, but by less than 
3% for SNP densities of greater than one SNP per 5 kb. This difference was halved with 
the use of only 23 unphased individuals in the smaller segments owing to upward biases in 
observed r2 from small number of individuals (Figures 3.1 and 3.2). 
The estimated number htSNPs confirmed that significant genotyping reductions in disease 
association studies can be achieved. I estimated that there are up to 1.4 million htSNPs 
genomewide. A very recent study by Carlson et al. (2004) using a similar dataset and 
method of htSNP selection, agreed with my result, by estimating 4.2 htSNPs per 10 kb for 
pair-wise r2 > 0.8 (equivalent to 1.3 million SNPs for 3,200 Mb genome). My results also 
show that the number of htSNPs is a function of initial SNP map density. The number of 
htSNPs of the complete map was almost double that of the one SNP per 2.5 kb map. 
Sparse maps requiring lesser htSNPs, perhaps due to reduced sample haplotype diversity. 
Therefore, genomewide number of htSNPs derived from studies of incomplete SNP maps 
will almost certainly be underestimates (Goldstein et al. 2003). 
The numbers of htSNPs suggested here are likely to be the upper limits. The use of 
haplotypes, or otherwise combining SNP frequencies, for htSNP selection should be more 
efficient than using only pair-wise r2, but might require larger sample sizes for reliability 
(Meng et al. 2003). Selecting htSNPs based on the dataset in Table 3.1 suggested that 
haplotype methods (Chapman et al. 2003) may lead to -30% further reduction in 
genotyping. Larger regions of strong LD will also be important. Therefore, the actual 
number of htSNPs required would be less than what is suggested here, almost certainly less 
than one million, and perhaps around 500,000. The genotyping of these many htSNPs in 
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say 1,000 cases and 1,000 controls, resulting in 1012 genotypes, is currently prohibited by 
cost and throughput. The rapid improvement in chemistry (Syvanen 2001), robotics, 
multiplex and pooling methods (Sham et al. 2002), will hopefully resolve this problem in 
the near future. 
Given the likely large number of genetic variants for common diseases, even SNP maps of 
one common SNP per 2.5 kb covering a moderate proportion of common SNPs would be 
of value to begin association mapping (Figure 3.5B). In the long term, however, 
geneticists searching chromosome regions to detect disease associations need to be able to 
confidently determine the involvement of at least the common SNPs, owing to 
uncertainties about the number, penetrance and allelic frequencies of causal variants. It 
has been shown here that to achieve comprehensive and robust SNP maps, density focused, 
PCR-based, SNP discovery efforts at the minimum of one common SNP/kb density are 
required for parts of the genome. It will, therefore, be beneficial for disease mapping 
studies, both direct and indirect, that the on-going large-scale HapMap map effort 
(International HapMap Consortium 2003) be integrated with the parallel construction of a 
SNP map of the 200,000- 300,000 exons of the human genome by comprehensive 
resequencing. 
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Chapter 4 Candidate Gene Studies 
4.1 Background 
Several approaches exist for selecting candidate .genes in the study of common diseases 
and these may be divided into functional and positional (McCarthy et al. 2003). Functional 
candidacy is based on the presumed pathophysiological involvement of the proteins 
encoded by the genes. Currently, it is probably the most common approach for selecting 
disease candidates. However, owing to the numerous and unknown genes and 
physiological pathways for any complex trait, functional selection is difficult, and a large 
number of null and borderline results have been produced with only few positive results 
substantiated (Hirschhorn et al. 2002; Ioannidis et al. 2003). 
Positional candidacy can be from a number of sources. Perhaps the most commonly taken 
approach at present is through linkage analyses, which, as discussed in Chapter 2, provide 
high prior probabilities for strong effects if linkage can be substantiated. Without the 
knowledge of functions, altered levels of mRNA or proteins in tissues of relevance to the 
disease can also provide disease gene candidacy (Iwai and Inagami 1991; lwai et al. 1994). 
Orthologue mapping using animal models of disease, such as NOD in the case of TlD, can 
also identify genomic regions of interest. The utility of combining multiple selection 
strategies should result in candidates with better odds for disease association. 
Using different combinations of functional and positional methods, I examined four 
candidate genes/regions for their involvement in TlD. 
4.1.1 HERV-K18 I CD48 locus, human chromosome lq23 
Several lines of evidence provides functional candidacy for the Human Endogenous 
Retrovirus K18 (HERV-Kl8) I CD48 locus in the aetiology of TlD. HERV-K18 encodes 
for a T-cell superantigen (SAg), and T cells with HERV-K18 SAg reactive T cell receptor 
(TCR) V/37 chains were found to be enriched in the pancreas, spleen (Conrad et al. 1994; 
Somoza et al. 1994) and circulation (Luppi et al. 2000) at the onset of TlD. HERV-K18 
mRNA expression was also enhanced in inflammatory lesions of patients with recent onset 
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disease (Conrad et al. 1997). HERV-K18 transcription and SAg function in cells capable of 
efficient presentation are induced by proinflammatory stimuli such as viruses and 
interferon-a (Ioannou and Isenberg 2000; Stauffer et al. 2001; Sutkowski et al. 2001; 
Jaeckel et al. 2002). HERV-Kl 8 SAg may thus trigger progression of disease to insulitis, 
or from insulitis to overt diabetes, and allelic variation of HERV-K18 or the DNA flanking 
it, the CD48 gene, might modulate genetic susceptibility (Stauffer et al. 2001). 
CD48 has four exons spanning 33 kb of human chromosome lq36. It contains HERV-Kl 8 
in intron 1. CD48 is a glycosylphosphatidylinositol-anchored45 kDa molecule with 
expression tightly regulated and restricted to lymphocytes, macrophages, and dendritic 
cells (Thorley-Lawson et al. 1982). CD48 binds to 2B4, which is broadly expressed in 
leukocytes, and mediates non-MHC-restricted cytotoxicity by NK cells (Brown et al. 1998; 
Tangye et al. 2000). CD48 binds also to CD2, a molecule that promotes T cell-APC 
adhesion and transduces T cell activation signals (Kato et al. 1992). CD48 knockout mice 
demonstrated impaired CD4+ T cell activation (Gonzalez-Cabrero et al. 1999). However, 
the significance of CD48 in autoimmunity is unclear. 
HERV-Kl 8 is 9,235 bp in length and its haplotype structure in the European population has 
been previously characterized (Stauffer et al. 2001). Three main haplotypes were 
identified and differed in amino acid sequence at five positions within the SAg coding 
region (Stauffer et al. 2001). Two of them have or could have biochemical consequences 
for SAg structure and function, namely a tyrosine to cysteine substitution in haplotypes 1 
and 3 at position 97, and a premature stop codon in haplotype 1 at position 154. The latter 
variant produces a soluble C-terminally truncated SAg protein for haplotype 1, and full 
length envelope proteins requiring intracellular cleavage for haplotypes 2 and 3. The 
tyrosine to cysteine substitution in haplotypes 1 and 3 could interfere with intra- and 
interchain disulfide bonding that is critical for the maturation of secreted and membrane 
proteins. Despite these differences, the three HERV-Kl 8 alleles all encode SAgs with 
indistinguishable capacity to stimulate mature T cells and T cell hybrids. 
In order to evaluate the association of HERV-K18 polymorphisms with TlD, a family-
based association study involving 14 single nucleotide polymorphisms (SNPs) was 
conducted, focusing on the main haplotypes of HERV-Kl 8 and was flanked by CD48 SNPs 
to delimit LD. 
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4.1.2 IDDM7, human chromosome 2q32 
Linkage of TlD to human chromosome 2q32 was suggested by the first human genome-
wide TlD linkage analyses with a maximum lod scores (MLS) of 1.2 using 96 UK families 
(Davies et al. 1994). In a follow up linkage scan of chromosome 2, Copeman et al. (1995) 
used 171 UK and 94 US families (including those used by Davies et al. (1994)) and 
demonstrated a MLS of 1.3 centred on the microsatellite D2S152. Families from US, but 
not UK, further demonstrated association with allele 228 of D2S152 (P = 0.001). In the 
same study, this association was supported in 103 Sardinian (P = 0.014) and 31 Italian (P = 
0.035) families, but not in 48 Danish families (Copeman et al. 1995). This locus was 
designated IDDM7. 
Attempts to replicate the association of D2Sl 52 with TlD showed mixed results. A 
Japanese study involving 164 TlD cases and 155 controls supported a weak association (P 
= 0.02) (Fu et al. 1996). Another study using 257 Florida Caucasian cases and 370 
controls, and 90 Taiwan Chinese cases and 169 controls, provided no evidence of 
association (Luo et al. 1995b). A large study consisting of samples from eight populations 
totalling 1,551 families (UK, n = 360; US, n = 294; Sardinia, n = 180; Italy, n = 162; 
Denmark, n = 54; Finland, n = 215; France, n = 82 and Romania, n =204), including 
overlapping families from Copeman et al. (1995), showed evidence of association in US (P 
= 0.005) and Sardinian (P = 0.01) populations, and an overall 52.3% transmission of allele 
228 of D2Sl 52 (P = 0.05), but not in the other six populations individually (Esposito et al. 
1998). These results suggest the potential for the existence of mild to moderate disease 
variants in LD with D2S152. 
Two recent linkage studies for TlD provided further support of linkage in 2q32. Cox et al. 
(2001) analysed 767 families, including those previously studied by Copeman et al. (1995), 
and provided suggestive evidence for linkage with a maximum LOD of 2.62. The study by 
the European Consortium for IDDM Genome Studies (2001) consisting of 406 
Scandinavian families provided LOD of 0.79 for chromosome 2q. The differences in 
markers used and method of analysis, makes the direct combination of results from these 
two studies difficult. Since their publication, both of those datasets were made available 
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by the Type 1 Diabetes Genetics Consortium (TlDGC, www.tldgc.org), and combined 
analysis can be conducted. 
The IDDM7 linked region has a number of candidate genes for TlD. These include CTLA-
4, which has significant TlD association substantiated in a large multi -population study 
conferring a very modest allelic risk of 1.07 for the disease (Ueda et al. 2003), and 
NeuroD/BETA2, which has not been consistently associated with TlD (Iwata et al. 1999; 
Vella et al. 2004). However, these genes are located more than 10 Mb away from the 
disease associated microsatellite D2S152, and have very weak effects, insufficient to 
contribute much to linkage. Therefore, the potential exists for another TlD gene in LD 
with D2Sl 52. This was investigated using an indirect mapping approach. 
4.1.3 PDCD2 and PSMBl in IDDM8, human chromosome 6q27 
Linkage of TlD to chromosome 6q27 - 6qter was first suggested by the genome scan of 
Davies et al. (1994) with MLS of 1.2. This locus was later designated IDDM8. Luo et al. 
(1996) demonstrated significant linkage in IDDM8, with MLS of 5.0, in a meta-analysis of 
datasets from US, Italy and UK (Luo et al. 1995a; Davies et al. 1996). IDDM8 linkage 
was further supported by a study involving French, N. African, US and Danish families 
(Delepine et al. 1997). A recent analysis of 767 multiplex families from UK and US (with 
overlapping families from previous studies) provided some positive evidence of linkage at 
IDDM8 with LOD = 1.81, and demonstrated LOD = 3.69 in subgroup analysis of sib-pairs 
with disease onset ~11 years (Cox et al. 2001). However, linkage of 6q27 with TlD has 
not been consistently demonstrated (European Consortium for IDDM Genome Studies 
2001). Paterson et al. (1999) suggested a possible paternal origin effect for linkage in this 
region. 
Owerbach (2000) studied the association of TlD with microsatellite markers of IDDM8. 
He used ten microsatellite markers spanning 1 Mb of 6q27 and identified 18 haplotypes. 
Six of these haplotypes demonstrated marginal evidence of association with TlD (P < 
0.05) but none had P < 0.01. There were no obvious relationships in the distribution of the 
associated haplotypes with each other except that they were all in the terminal 500 kb of 
6q27. Myerscough et al. (2000) showed association of a microsatellite marker in the 
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terminal 500 kb with rheumatoid arthritis - this marker, D6S446, was studied by 
Owerbach (2000) but no association was demonstrated. On balance, the published 
evidence to indicates the existence of a TlD gene (or genes) in 6q27, but without a precise 
location. 
A project involving in ten members of my laboratory (the Diabetes and Inflammation 
Laboratory or DIL) was set up to analyse the contribution of genes in the 1DDM8 region to 
TlD. My participation with the project included laboratory work for two genes: Program 
Cell Death 2 (PDCD2) and Proteasome Subunit Beta-Type 1 (PSMBJ); and the 
investigation of the effect of age of onset on linkage in this region. PDCD2 is the last gene 
on human 6q-ter and shows high homology with rat gene Rp8 that is involved in program 
cell death (Kawakami et al. 1995). In humans, PDCD2 is repressed by BCL6, a gene that 
regulates apoptosis (Baron et al. 2002). PSMBJ encodes for a proteasome subunit and is 
essential in breaking down intracellular proteins. Proteasomes are important in antigen 
processing of MHC class I-restricted antigens (Fehling et al. 1994; Van Kaer et al. 1994), 
and may be influenced by cytokines such as interferon gamma (Akiyama et al. 1994). 
Raised levels of autoantibodies against proteasomes have been found in patients with 
multiple sclerosis (Mayo et al. 2002). The involvement of PDCD2 and PSMBJ in 
autoimmune diseases is thus possible. The two genes are 24 kb apart and separated by the 
gene for TATA Box Binding Protein (TBP). Interestingly orthologues for PSMBJ, TBP 
and PDCD2 are syntenous in yeasts, C.elegans, Drosophila, snakes and mammals 
(Trachtulec and Forejt 2001). 
4.1.4 VIP, human chromosome 6q25 
Vasoactive intestinal ·peptide (VIP) is a very important 28-amino acid peptide with a wide 
variety of biological functions. VIP is involved in regulation of the gut, and has 
cardiovascular functions such as vasodilatation and stimulating myocardial contractility. It 
has also known functions in neuronal development, control of circadian rhythm, and 
immune regulations (Gressens et al. 1993; Shen et al. 2000; Delgado et al. 2002). 
VIP is both a positional and functional candidate gene for TlD. It resides in human 
chromosome 6q25, corresponding to human TlD linked region IDDMS (Davies et al. 
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1994). Linkage to IDDMS, however, has not been readily replicated and some evidence 
suggests that it might be the transient neonatal diabetes locus (Cave et al. 2000). I first 
noted VIP as a potential candidate for TlD in a search for G-protein coupled receptors 
(GPCRs) and their ligands in TlD linked regions. Approximately 40% of current small 
molecule drugs target GPCRs, and hence genetic variants of one of these genes, or their 
ligands, might indicate possible therapeutic opportunity in TlD and other autoimmune 
diseases (Sadee et al. 2001). The immunological effects of VIP further support its 
candidacy. It has been suggested that an increased ratio of Thl/Th2 cells contributes to the 
development of autoimmunity (Strachan 1989). VIP preferentially induces T cell 
differentiation towards a Th2 response following antigen stimulation (Delgado et al. 1999). 
lntraperitoneal injection of VIP to mice with collagen-induced arthritis, a murine 
experimental model of rheumatoid arthritis (Trentham et al. 1977), suppressed Thl cell 
function and differentiation, enhanced the function of Th2 cells, and resulted in decreased 
incidence and severity of arthritis (Delgado et al. 2001). In those animals, decreased 
antibodies to collagen was also observed suggesting B-cell responses might also be 
important. The potential role for VIP genetic variants in TlD was investigated. Owing to 
the abundance of SNPs in public databases in that genomic region, an indirect approach 
was taken to evaluate possible TlD association. 
4.2 Methods 
Family based association analyses with SNPs were performed. 
4.2.1 Subjects 
4.2.2.1 Subject for genotyping in association studies 
The study population consisted of 754 families each composed of two parents and at least 
two affected offspring. This included 472 Diabetes UK Warren 1 multiplex families (Bain 
et al. 1990), and 282 multiplex families ascertained in the USA from the Human Biological 
Data Interchange (Lernmark et al. 1990). 
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4.2.2.2 Subjects for sequencing 
For the IDDM8 project in which SNPs were discovered by sequencing, the sequencing 
panel consisted of 96 individuals. Forty-eight of these were parents of IDDM81inked 
families from Mein et al. (1998), and 48 were unaffected controls. 
4.2.2 Sequencing 
For IDDM8 genes, PDCD2 and PSMBJ, resequencing was performed in 96 unrelated 
individuals to harvest SNPs and construct haplotypes. Genomic DNA sequences were 
downloaded from Ensembl, with regions of interest noted by pair-wise alignment of 
genomic and mRNA sequences. For the relatively small 7 kb PDCD2 gene, the entire 
gene, including introns, was resequenced from 3 kb upstream to 3 kb downstream. For 
PSMBJ, only exons and 3 kb up- and downstream were sequenced. 
PCRs were carried out in final volumes of 15 µl containing 25 ng of genomic DNA, 
0.2mM dNTPs, 1.5mM MgC}z, 0.2 µM of each primers and 0.6 units of BioTaq (Bioline). 
Cycle temperature conditions were 94 °C for 5 minutes, followed by 25 to 35 cycles of 
94 °C for 45 seconds, 60°C to 65°C for 45 seconds and 72°C for 90 seconds, followed by 
final extension at 72°C for 10 minutes. PCR products from the outer nest were diluted 1 in 
100, and 5 µl was used as template for the inner nest with conditions above. 
Nested PCR products were treated with shrimp alkaline phosphatase (SAP) and 
exonuclease-I before sequencing. Cycle sequencing was performed according to the 
manufacturer's protocols using an ABI PRISM BigDye Terminator Sequencing kit with 
AmpliTaq DNA polymerase (Perkin Elmer). Sequencing primers were the same as those 
used for the inner nest of PCR. Sequencing products were then purified by SAP and 
precipitated in ethanol. The final products were read by ABI3700 machines and graphical 
sequence files were produced. 
Sequence analyses and polymorphism detection from graphical sequences files, were 
performed using Staden programs PreGAP4 and GAP4 including the utility of trace_diff 
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and hetscanner routines (Bonfield et al. 1998; Staden et al. 2000). After SNPs had been 
identified and genotypes assigned, these information was loaded into the laboratory's 
database. 
4.2.3 SNP selection 
SNPs were derived from sequencing either in house by collaborators, or from public 
databases: dbSNP (Smigielski et al. 2000), JSNP (Hirakawa et al. 2002), and SeattleSNPs 
(Carlson et al. 2003). 
dbSNP (www.ncbi.nlm.nih.gov/SNP/) is the international central database for di-allelic 
polymorphisms. SNPs from other sources will generally be submitted to dbSNP, given 
some time delay. Build 118 of dbSNP contains a total of 5.8 million SNPs, with 2.3 
million of these validated. A problem with using SNPs from dbSNP is that between 17% 
and 40 % of reported SNPs in that databases were noted not to be polymorphic in 
resequencing studies (Carlson et al. 2003; Reich et al. 2003). For consistency in this 
thesis, dbSNP reference numbers (starting with rs#) are used for the identification of SNPs 
derived from all public sources (where possible), and SNPs discovered in my laboratory 
have DIL reference numbers. JSNP (snp.ims. u-tokyo.ac.jp) is a database of nearly 200,000 
SNPs derived from PCR based resequencing of 24 Japanese individuals in gene containing 
regions of the human genome (Haga et al. 2002). SeattleSNPs (pga.mbt.washington.edu) 
is a database of SNPs derived from resequencing 23 European Americans and 24 African 
Americans in genes of predominantly immunological or haematological interests (Carlson 
et al. 2003). That database provides genotype information for the resequenced genes (see 
Chapter 3). 
4.2.3.1 HERV-Kl 8 I CD48 
HERV-Kl 8 SNP details were provided by collaborator Dr. B. Conrad of the University of 
Geneva. Genotyping of these SNPs required the initial PCR amplification of a 3 .1 kb 
region to isolate HERV-KI8 from other HERV sequences in the genome using primers 5'-
ATCAGATCTAACACTAGTAACCCATCAGAGATGCAAAGAAAAGC-3' and 5'-
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CATGAGACAAT ATTT AAAGGTTTGGGGTCGACTGAGCGGCCGCAAT-3' (Stauffer 
et al. 2001). SNPs in the flanking CD48 were derived from JSNP (Appendix I). 
4.2.2.2 IDDM7 
SNPs were selected from public databases around the rnicrosatellite D2S152 . From 
SeattleSNPs, full genotype data was available for the nearby Tissue Factor Pathway 
Inhibitor gene (TFPI). For SNPs in this gene, only one of each pair of correlated SNPs 
with r2 ~ 0.8 and MAF ~ 0.1 was chosen. 
4.2.2.3 PSMBJ and PDCD2 in IDDM8 
SNPs were derived from sequencing 96 individuals. SNPs genotyped included candidate 
SNPs, such as exonic and promoter variants, and htSNPs. htSNPs were chosen from SNPs 
with MAF > 3% using program HTSEARCH (Clayton, 
www-gene.cimr.cam.ac.uk/clayton/software/stata/) with minimal allelic r2 of 0.8 
(Chapman et al. 2003). Allelic r2 uses the combination of SNP alleles and their 
frequencies in the prediction of SNPs not genotyped. My simulations based on regions in 
Chapter 3 suggest that htSNP selection using this method requires only 32 individuals re-
sequenced, and reliability is very high for 96 individuals (data not shown). 
4.2.2.4 VIP 
Five SNPs derived from JSNP were genotyped over the 10 kb gene. These were 
rs2756117, rs3757070, rs3799142, rs3823082 and rs688136. 
4.2.4 Genotyping 
Genotyping in families was done using TaqMan ™ probe sets designed by Applied 
Biosystems (UK), and performed according to manufacturer's recommendations. 
Fluorescence analysis using an ABI 7900HT instrument (Applied Biosystems, UK) 
allowed genotypes to be determined from the clustering of the products into two groups of 
homozygotes and one group of heterozygotes for each SNP. 
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4.2.5 Statistical analyses of disease association 
Statistical analyses for association were performed using Genassoc routines in the 
statistical package STATA (www-gene.cimr.cam.ac.uk/clayton/software/). The 
transmission disequilibrium test (TDT) examines the proportions of transmission of alleles 
from heterozygous parents to affected offspring (Spielman et al. 1993). It is a McNamar 
and scores alleles transmitted against alleles not transmitted. GTRR is the genotype based 
equivalent of TDT, and is similar to a matched case-control study constructed by 
comparing each "case" (an affected offspring) with a set of three "pseudo-controls" 
comprising the other three possible genotypes for the offspring of these parents. For TDT 
and GTRR, the "robust cluster (pedigree)" option was used to provide valid tests of 
association for more than one affected member per family. 
SNP association based on htSNPs could be analysed in two ways. First, untyped SNPs that 
are tagged by htSNPs could have their expected level of association imputed and then be 
tested individually. Alternatively, a multi-variant test of all SNPs may be used to provide 
one final statistic. The program MLTDT (from the above STATA package) was used to 
analyse the association of htSNPs. It is a multi-variant t-test based on the counts of alleles 
transmitted to affected offspring for SNPs that have been genotyped which are generally 
htSNPs (Chapman et al. 2003). A significant MLTDT results imply overall increases in 
allele transmission. The region of interest is thus implicated in the disease, although SNPs 
may or may not be individually associated. If there are n SNPs in a region, and h of these 
are chosen as htSNPs, then MLTDT hash degrees of freedom. Since his generally less 
than n, MLTDT gains extra power owing to smaller degrees of freedom. 
4.2.6 Re-evaluation of linkage in IDDM7 
Using families available from T1DGC consisting a total of 1,175 multiplex families (768 
UK/US and 493 Scandinavian), the linkage of chromosome 2 was reanalysed using 
GENEHUNTER (Kruglyak et al. 1996) that I modified to allow larger numbers of 
families. 
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4.2.7 Analyses of age-of-onset effects for linkage in IDDM8 
Microsatellite genotypes and age-of-onset information for 378 UK and 326 US families 
were available from previous genome scans (Cox et al. 2001). Since age-of-onset was not 
normally distributed and cannot be readily transformed to be so, a non-parametric 
approach using the program IBDReg was adopted (Clayton, www-
gene.cimr.cam.ac.uk/clayton/software/). The program performs linkage analyis by logistic 
regression of IBD sharing allowing for covariates (Holmans 2002). Interactions between 
allele sharing and sibling pairs' age-of-onset averages and differences were examined. 
IBD distributions required for input into IBDReg were estimated by GENEHUNTER, and 
converted to appropriate format by the program GH2Stat (Clayton, www-
gene.cimr.cam.ac.uk/clayton/software/). 
4.3 Results 
4.3.1 HERV-K18 I CD48 
Five HERV-K18 SNPs and nine SNPs in CD48 were genotyped (Figure 4.1). Table 4.1 
shows the results of allelic and genotypic association analyses. Evidence of TlD 
association (P = 0.0026) was found for three HERV-K18 SNPs at nucleotides 8146, 8594, 
and 8460 (Table 4.1). These three SNPs were in perfect LD (r2 > 0.98) with each other 
and belonged to the same previous! y identified haplotype, HERV-Kl 8. 3, that is unique in 
having the combination of a tyrosine at position 97 and no stop codon at position 154 
(Stauffer et al. 2001). US and UK samples showed similar results with 56% and 54% 
transmission respectively. 
Hardy-Weinberg equilibriums (HWE) were observed for all SNPs. Figure 4.1 shows the 
pattern of LD of the CD48 locus with three regions of high LD and breaks at rs3766367 
and rs352683. 
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Table 4.1 Association analyses of SNPs in HERV-K18 I CD48 locus with TlD. 
Allele Minor Allele P values Genotype Relative Risks 
TDT TDTnon-
Minor Major Frequency transmitted transmitted TDT robust Minor homozygotes 
rs3795324 A C 0.183 379 365 0.533 1.22 (0.81 - 1.84) 
rs3766366 A G 0.098 175 208 0.113 1.40 (0.57 - 3.45) 
rs3766367 A G · 0.019 40 60 0.0817 too rare 
rs3796502 A T 0.263 475 531 0.0890 1.07 (0.81 - 1.40) 
rs2295615 G C 0.137 303 337 0.195 1.08 (0.65 - 1.78) 
HERV-6836 G A 0.383 678 652 0.492 1.12 (0.93 - 1.36) 
HERV-7007 A G 0.446 655 612 0.232 1.03 (0.86 - 1.23) 
HERV-8148 A G 0.214 370 450 0.00821 0.98 (0.68 - 1.41) 
HERV-8594 T C 0.216 374 459 0.00432 0.89 (0.62 - 1.27) 
HERV-8460 C T 0.218 385 476 0.00260 0.84 (0.59 - 1.19) 
rs3766369 G A 0.347 621 588 0.364 1.17 (0.94 - 1.45) 
rs352683 A G 0.214 391 427 0.232 1.17 (0.83 - 1.64) 
rs352684 A G 0.438 623 671 0.197 1.10 (0.91 - 1.32) 
rs352685 G C 0.322 605 559 0.170 1.13 (0.91 - 1.40) 
Genotype relative risks were based on GTRR analyses with heterozygote risks = 1 and 95% confidence intervals shown. 
* P < 0.05 
t P < 0.01 
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Major homozygotes 
0.99 (0.84 - 1.17) 
1.24 (0.99 - 1.55) 
1.67 (1.06 - 2.63)* 
1.19 (1.02 - 1.39)* 
1.15 (0.96 - 1.37) 
1.01 (0.87 - 1.17) 
0.90 (0.77 - 1.07) 
1.27 (1.07 - l.49)t 
1.25 (1.07 - l.47)t 
1.25 (1.07 - l.46)t 
1.00 (0.86 - 1.16) 
· 1.17 (0.99 - 1.38) 
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Figure 4.1 LD pattern of SNPs genotyped in the HERV-K18 I CD48 locus . 
4.3.2 IDDM7 
Re-analyses of linkage using data from TlDGC for chromosome 2 demonstrated linkage 
centred at D2Sl52 with MLS of 3.12 and estimated As of 1.20. 
Twenty-seven SNPs were successfully genotyped in 197 kb surrounding D2S152 (see 
figure). At the time qf the experiment, SNP availability in the flanking genomic region 
was very poor and only an additional five SNPs were successfully genotyped in an attempt 
to delimit LD. LD for D2Sl52 and surrounding SNPs was limited 1.2 Mb between 
rs2018314 and rs2033838. During the writing of this thesis, genotypes for SNPs in 60 
CEPH trio-families (two parents and one offspring) were made available from the 
HapMap project (www.hapmap.org). Using that data, the LD for most SNPs around 
D2S152 were delimited to less than 753 kb and within rs1451557 and rs4622677 
(Appendix 2). 
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There were no association found between any of the SNPs genotyped and TlD (Table 4.2). 
MLTDT analysis was also non-significant (x2 2s ctf = 27.2, P = 0.35). HWEs were 
observed. The 27 SNPs surrounding D2Sl 52 can be clustered into seven groups that 
exhibited r2 > 0.5 with each other, and 11 groups that exhibited r2 > 0.8 . No allele of the 
SNPs studied demonstrated correlation with r2 > 0.8 with the previously noted TlD 
associated allele of D2Sl52. 
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Figure 4.2 Genomic region of IDDM7. Twenty-seven SNPs were genotyped (DIL polymorphisms) in a 197 
kb region around D2SI52 to analyse association with TlD. SNPs from HapMap (January 2004) also noted. 
Other SNPs genotyped in the larger 1.2 Mb region for delimiting LD are not shown. 
4.3.3 PSMBJ and PDCD2 in IDDM8 
4.3.3.1 Association 
The sequencing of PDCD2 and PSMBJ yielded 39 and 20 SNPs respectively. In PDCD2, 
no SNPs were identified in the coding sequence, although exon 1 was not sequenced after 
repeated PCR failures owing to high GC content. Two exonic candidate SNPs were 
identified in PSMBJ. These were (in relative positions to the ATG start codon) a common 
(38%) nucleotide 31 C 7 G substitution (DIIA064) leading to a praline to alanine change 
at amino acid 11, and a C7 T substitution (DIIA063) at position - 6. 
SNPs in PDCD2 and PSMBJ exhibited high LD (D' > 0.8) both within and between genes. 
In PDCD2, 11 htSNPs were selected and genotyped. The tagging of PSMBJ utilized two 
candidate SNPs (above), four PDCD2 SNPs, and two additional SNPs in PSMBJ . The 
htSNPs for the two genes were not selected jointly owing to that htSNP selection for 
PDCD2 was four months ahead of those for PSMBJ. 
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Table 4.2 Transmission analysis of SNPs in IDDM7 
SNP Chromosome 2 Number of Allele Transmitted Untransmitted Pvalue 
position parents Frequency 
rs1992898 187693683 1262 0.75 1916 1891 0.435 
rs2197138 187696384 1263 0.25 618 648 0.355 
rs2018314 187987553 1207 0.22 500 536 0.229 
rs840569 188375668 1065 0.34 723 732 0.774 
rs1528233 188409788 *LD with r2 > 0.8 with rs840569 
rs696092 188412757 LD with r2 > 0.8 with rs840569 
rs3771095 188413655 1285 0.88 2296 2270 0.266 
rs698590 188417366 LD with r2 > 0.8 with rs840569 
rs698588 188417467 1240 0.35 861 868 0.837 
rs858745 188419350 1065 0.86 1858 1851 0.763 
rs2308082 188421227 1281 0.86 2226 2214 0.626 
rs858750 188421595 1273 0.86 2208 2197 0.656 
rs3815524 188426865 1321 0.12 295 310 0.528 
rs3771089 188432689 1260 0.49 1230 1234 0.913 
D2S152 188434139 T1 D associated microsatellite 
rs860846 188437471 1279 0.68 1748 1734 0.685 
rs3771084 188446176 1205 0.44 1045 1062 0.633 
rs1398061 188460528 LD with r2 > 0.8 with rs840569 
rs3771074 188488253 1316 0.96 2539 2532 0.622 
rs3771073 188488760 1298 0.59 1529 1541 0.744 
rs3771072 188491991 1199 0.95 2302 2279 0.140 
rs1355519 188511147 1256 0.70 1754 1766 0.722 
rs1912847 188527816 LD with r2 > 0.8 with rs840569 
rs763684 188536766 1263 0.42 1052 1064 0.744 
rs8176580 188537789 1188 0.70 1670 1673 0.926 
rs8176531 188546250 1270 0.82 2087 2110 0.416 
D1L6763t 188551243 1288 0.70 1847 1802 0.189 
rs8176508 188553606 1299 0.63 1656 1623 0.359 
rs8176605 · 188558653 1290 0.95 2448 2459 0.486 
rs2300412 188570418 LD with r2 > 0.8 with rs763684 
rs3755248 188572775 LD with r2 > 0.8 with rs840569 I 
rs2033838 189071303 1333 0.85 2237 2275 0.164 I rs1354906 189649361 1185 0.68 1671 1615 0.085 
* SNPs noted to be in strong LD previously genotyped SNPs had genotyping discontinued 
after 386 individuals. 
t No dbSNP number found. 
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Table 4.3 Transmission analysis of SNPs in IDDM8 
PDCD2 
SNP Chromosome Allele Information Transmitted Untransm itted Pvalue 
6 position frequency* sourcet 
OIL1597 170740536 0.03 imputed 89 104 0.272 
OIL1595 170742301 0.06 imputed 137 119 0.303 
OIL 1594 170742421 0.53 genotyped 1675 1681 0.854 
OIL1592 170743040 0.48 genotyped 1451 1457 0.871 
OIL 1591 170743410 0.97 genotyped 2677 2662 0.272 
OIL 1590 170743738 0.55 imputed 1829 1805 0.586 
OIL 1589 170743768 0.49 imputed 849 858 0.851 
OIL 1588 170744202 0.39 genotyped 1074 1080 0.871 
OIL 1587 170744717 0.81 imputed 2348 2356 0.688 
OIL 1585 170744872 0.87 imputed 1692 1686 0.871 
OIL1583 170745254 0.03 imputed 89 104 0.272 
OIL 1581 170746893 0.37 genotyped 1091 1085 0.875 
OIL1579 170747112 0.92 genotyped 2621 2642 0.242 
OIL 1578 170747302 0.96 imputed 2677 2662 0.272 
OIL 1577 170747552 0.03 imputed 89 104 0.272 
OIL1576 170748002 0.23 imputed 1668 1664 0.918 
OIL 1575 170748365 0.33 genotyped 1235 1216 0.609 
OIL1575 170748365 0.67 imputed 1675 1681 0.854 
OIL 1574 170748609 0.46 genotyped 1450 1458 0.833 
OIL1573 170749357 0.46 imputed 1315 1297 0.581 
OIL1572 170749429 0.46 imputed 1447 1465 0.584 
OIL 1571 170749520 0.04 imputed 2677 2662 0.272 
OIL1570 170750527 0.40 genotyped 1106 1085 0.566 
OIL1567 170752140 0.38 imputed 1091 1085 0.854 
OIL1565 170752243 0.95 genotyped 2629 2647 0.303 
OIL1563 170753071 0.14 genotyped 400 388 0.641 
OIL1562 170753153 0.48 imputed 1317 1307 0.796 
OIL 1561 170753166 0.40 imputed 1091 1085 0.854 
PSMBJ 
SNP Chromosome Allele Information Transmitted Untransmitted p-value 
6 position frequency* sourcet 
OIL4085 170699334 0.56 Imputed 1571 1569 0.9583 
OIL4084 170701114 0.55 Imputed 1571 1569 0.9583 
OIL4082 170709070 0.88 Imputed 2395 2408 0.5867 
OIL4080 170711685 0.04 Imputed 103 123 0.1493 
OIL4079 170711861 0.04 Imputed 103 123 0.1493 
OIL4078 170711898 0.94 Imputed 2673 2687 0.4052 
OIL4071 170714391 0.96 genotyped 2711 2693 0.1979 
OIL4070 170714554 0.96 Imputed 1546 1520 0.4529 
OIL4068 170714841 0.90 imputed 2682 2695 0.4178 
OIL4066 170718538 0.94 genotyped 2602 2610 0.6699 
OIL4065 170718560 0.42 imputed 1184 1198 0.6834 
OIL4064 170718809 0.62 genotyped 1706 1690 0.6625 
OIL4063 170718845 0.94 genotyped 2659 2673 0.4173 
OIL4062 170718965 0.97 imputed 2707 2688 0.1511 
* Allele frequencies are from 96 unrelated individuals in sequencing. 
t Association analyses used information from genotyping or imputed from htSNPs. 
There was no significant T lD association with SNPs in PDCD2 and PSMBJ using either 
single locus tests (Table 4.3). Multi-locus tests were also none significant (P > 0.05). 
4.3.3.2 Linkage and age-of-onset 
Using the logistic regression approach of IBDReg, the average, minimum and maximum 
age-of-onset of sib-pairs showed similar and significant interactions with allele sharing in 
6q-ter (P = 0.002, Figure 4.4). Sib-pair age-of-onset differences did not show such an 
effect. Linear regression of allele sharing versus average age-of-onset gave a significant (P 
= 0.002), but weakly correlated effect (r2 = 0.012) with the formula: 
mean alleles shared= 1.174-0.0177 x (average age-of-onset) 
Linkage in chromosome 6q27 was improved when age-of-onset was entered as a covariant 
in linkage analyses (P = 0.00122) compared to without (P = 0.052). 
Analyses for the rest of the genome noted only two additional loci of interest. Significant 
interaction between allele sharing and age-of-onset averages was noted in the HLA region 
(P = 0.003). An interaction between age-of-onset differences and allele sharing was 
observed on chromosome lq41 (237cM from lp-ter, P = 0.005) with improvement in 
linkage using age-of-onset in as a covariant (P = 0.0023) compared to without (P = 0.058). 
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Figure 4.3 SNPs discovered in Dil,, and the genomic positions for thethree 6q telomeric genes. 
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Figure 4.4 IBDReg analysis of chromosome 6, showing (A) interaction between IBD sharing and within sib-
pair age-of-onset measures, and (B) the resultant linkage when sib-pair age-of-onset averages and differences 
were treated as covariants of allele sharing. The use of age-of-onset minimums and maximums as covariants 
of allele sharing provided similar results as when age-of-onset averages were used. 
4.3.4 VIP 
All five SNPs studied were in LD (D' > 0.7, except for one pair with D' = 0.66). Three 
SNPs showed some evidence of association with T1D (Table 4.4). Using a multi-locus 
test, there was a weak overall T1D association with SNPs in this locus (x2 5 df = 13.6, P = 
0.0185). Using data from HapMap, the LD for most SNPs around VIP was limited to 206 
kb from rs1407491 to rs178129 (Figure 4.5 and Appendix 2). 
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Figure 4.5 Genomic region around VIP, noting also positions of SYNEJ and MYCTJ. Data from 
HapMap (January 2004) delimits LD for SNPs around VIP to between rs140749I and rs178129. 
4.4 Discussion 
AL• 
The study of four candidate genes and regions for T1D demonstrated some evidence of 
novel disease association in two genes. 
4.4.1 HERV-K18 / CD48 
Three HERV-Kl8 SNPs showed evidence of association with T1D (Table 4.1). These 
three SNPs were in perfect LD (r2 > 0.98) with each other and the slight differences in their 
results is likely to be the product of different genotyping failure rates. Genotype based 
analyses suggest that the associated haplotype may be dominantly protective for the 
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Table 4.4 Association analyses of SNPs in the VIP locus with T1D 
Allele Minor Allele P values Genotype Relative Risks 
TDT TDTnon-
Major Minor Frequency transmitted transmitted TDT robust Minor homozygotes Major homozygotes 
rs2756117 G C 0.104 267 210 0.00995 0.91 (0.48 - 1.74) 0.76 (0.62 - 0.92)t 
rs3757070 A G 0.0715 153 192 0.0429 1.30 (0.62 - 2.71) 1.32 (1.04 - 1.66)* 
rs3799142 T C 0. 140 305 320 0.567 1.18 (0.75 - 1.86) 1.09 (0.91 - 1.32) 
rs3823082 C T 0.184 373 395 0.460 1.51 (1.08 - 2.12)* · 1.20 (1.01 - 1.43)* 
rs688136 T C 0.365 566 652 0.0137 0.83 (0.67 - 1.03) 1.12 (0.97 - 1.31) 
Genotype relative risks were based on GTRR analyses with heterozygote risks = 1 and 95% confidence intervals shown. 
* P <0.05 
t P <0.01 
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disease (P = 0.0061), but the final determination of the mode of inheritance will require 
much larger datasets due to the small number of individuals who are homozygous for the 
minor alleles. 
The observed associations between HERV-K18 SNPs and T1D can be explained in a 
number of ways. Given that the three associated SNPs were highly correlated with each 
other, HWE was observed, and the misinheritance rate was very low, associations due to 
technical errors (Gordon et al. 2001) seem unlikely. However, it is possible that our result 
is a statistical false positive, even given the functional candidacy of HERV-K18. 
Replication studies with other large data sets are thus warranted. If the associations are 
true positives, the causative variant may lie anywhere between rs3766367 and rs352683 - a 
30 kb region from intron 1 to exon 3 of CD48. The high degree of correlation between 
SNPs will make isolating the disease variant difficult (Ueda et al. 2003), and functional 
analyses would be warranted. 
In a small pilot study involving 74 Japanese T1D cases and 54 controls (Kinjo et al. 2001), 
no significant association was shown between HERV-Kl 8 SNPs at nucleotide positions 
6836 and 7007, and a borderline association (P = 0.03) was demonstrated only in subgroup 
analyses. Although the study was underpowered, it nevertheless noted significant 
differences in haplotype frequencies between the Japanese and Caucasian populations 
(Stauffer et al. 2001). 
The association of HERV-Kl 8 in the context of other genes involved in T1D warrants 
further examination. HERV-K18 SAgs are exquisitely MHC class II dependent (Stauffer 
et al. 2001; Sutkowski et al. 2001) and, therefore, genetic epistasis between the two loci is 
possible. However, giyen the moderate genetic effect noticed in this study, interaction 
analyses between HERV-K18 and HLA, as well as with other loci firmly established in 
T1D, will require much larger sample sizes to ensure statistica~ power, provided that the 
current primary association can be confirmed. The involvement of HERV-K18 in other 
autoimmune diseases also remains to be tested. The PCR assay and genotyping methods 
used here, and the knowledge of linkage disequilibrium structure in this genomic region, 
will facilitate those future investigations. 
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The HERV-Kl 8 locus appears to be unique among the endogenous retrovirus HERV-K 
family with respect to gene regulatory features that could predispose it to autoimmunity, 
namely its transcriptional induction by proinflammatory stimuli with immunopathological 
potential, and its constitutive expression in the thymus (F. Meylan and B. Conrad, 
· unpublished). Neither of these characteristics is shared by other known HERV-K 
proviruses. The observation that cis regulatory elements residing outside the HERV-Kl 8 
pro virus in the CD48 gene are required for these responses (B. Conrad, unpublished) could 
constitute at least in part a basis for why disease susceptibility has yet to be detected with 
other HERV loci. 
In summary, association between TlD and SNPs in the HERV-K18 I CD48 locus were 
demonstrated. Replication studies are now warranted to establish validity of this result. If 
those studies are successful, then the region will need to be fine mapped to identify the 
most likely causative variants, and functional studies should be pursued. 
4.4.2 IDDM7 
The study of 27 SNPs in 197 kb surrounding the TlD associated microsatellite D2Sl52 
demonstrated no significant association with the disease. These SNPs were in high LD 
with each other (D' > 0.7) and belonged to eleven clusters with r2 > 0.8. The 27 SNPs 
were not selected randomly, as eight of them were selected from the SNP and genotype 
information of TFPI in SeattleSNPs on the basis that they exhibited r2 < 0.8 with each 
other. TFPI is located 100 kb from D2Sl52. The eight TFPI htSNPs covered 43 common 
SNPs (MAF > 0.1) in that gene. Other SNPs were genotyped in this region without prior 
knowledge of their LD. Therefore, the genotyping of 27 SNPs around D2Sl 52 is 
equivalent to genotyping 62 (= 27 - 8 + 43) without the prior knowledge of LD. 
Although, as per Chapter 3, a map of 62 SNPs in a 197 kb region (- 1 SNP per 3 kb) is of 
insufficient density to exclude disease association, it does make the possibility of 
association less likely, especially in a region of high LD. It is also difficult to exclude the 
association ofrare or weakly acting disease susceptible variants. However, it is possible 
that the TlD association of D2S152 was a false positive, which may be either statistical or 
technical (Mitchell et al. 2003). 
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Using data from this experiment, the extent of LD for D2S152 was limited to a 1.08 Mb 
region from rs2018314 to rs2033838. Based on data from HapMap, LD for the SNPs 
around D2S152 was limited to 756 kb from rs1451557 to rs4622677 (Appendix 2). The 
difference between the two limits may be due to the lack of markers I genotyped outside 
the central 197 kb (Figure 4.2). However, even if LD was delimited to 1.08 Mb, there are 
only two known transcripts: the Calcitonin Receptor Like gene (CALCRL) and TFPI. How 
either of the genes might contribute to TlD is unknown. Nevertheless, LD of D2S152 
might extend well beyond the above boundaries as high mutation rates of a microsatellite 
can exhibit much longer range LD. 
4.4.3 PDCD2 and PSMBl in IDDM8 
Sequencing and association analyses provided no evidence of disease association for SNPs 
with MAF 2: 3% in PDCD2 and PSMBJ. The sample size of 754 multiplex families has 
greater than 90% power for a significance threshold of 0.05, in detecting association for a 
disease variant with population frequency of 3% and acting with an odds ratio of 1.5. 
Therefore, common variants in these two genes are unlikely to be strongly associated with 
TlD, but disease susceptible variants that are rare or contribute to mild increases in risk 
might still exist. 
Significant interaction was noted between age-of-onset averages and the degree of IBD 
sharing, with younger sib-pairs showing more linkage. This result is consistent with that of 
Cox et al. (2001), which, based on the same dataset, showed significant linkage only when 
limiting sib-pairs to those with age-of-onset of less than 11 years. However, despite the 
age-of-onset effect being statistically significant (P = 0.002), the proportion of variance 
explained is very low at/·= 0.012. Therefore, the usefulness of the age-of-onset effect in 
association mapping is unclear. Subgroup analyses based on age-of-onset did not 
demonstrate any significant results in PDCD2 and PSMBJ. 
The finding of age-of-onset effects in HLA is consistent with findings that patients with 
some haplotypes, tend to develop TlD at a younger age (Gillespie et al. 2002). The 
observed interaction with differences in sib-pair age-of-onset and IBD sharing in lq42 (P = 
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0.005) is novel, but may be a chance finding in a genomewide search (Lander and 
Kruglyak 1995). 
4.4.4 VIP 
VIP was selected as a candidate for TID based on both its location (IDDM5) and 
biological functions. Three of five SNPs in VIP demonstrated some evidence of 
association with T1D (Table 4.4). To my knowledge, no study has been published 
involving VIP polymorphisms in any common diseases. The results are marginal and 
replication studies, which will require large sample sizes, are warranted. 
If the positive associations can replicated, then fine mapping and functional analyses 
should follow to identify likely causal variant(s). None of the variants studied were protein 
coding. The mildly associated rs688136 (P = 0.014) is in the 3' UTR, 57 bp from the stop 
codon, and might be of functional significance. The correlation between the three 
associated variants were negligible (r2 < 0.1), suggesting the potential for either multiple 
disease susceptible variants or a disease susceptible variant in another haplotype not tested. 
Fine mapping will involve the resequencing of VIP to identify the most likely disease 
variants and to delimit LD. In JSNP, from where these variants were originally derived, 
only three out of seven exons were resequenced, hence the possibility for the existence of 
unobserved functional variants remains high. Results on marker density requirements from 
Chapter 3 also suggest that a significant proportion of undetected SNPs in this region 
would not have their variations captured by the current map of approximately one SNP per 
two kb. Based on the results generated using data from HapMap, the LD for SNPs around 
VIP was limited to a 206 kb region (Figure 4.5). In this region, there are two other known 
genes: Myc Target 1 (MYCTI), which contributes to apoptosis of cancer cells in vitro (Yin 
et al. 2002; Qiu et al. 2003); and a structural protein gene named Spectrin Repeat 
Containing Nuclear Envelope 1 (SYNEI) (Zhang et al. 2002; Gough et al. 2003). How 
these two genes might contribute to T1D is unclear. Given its known immunological 
effects, if the association to the test markers could be confirmed, the causative variant is 
most likely to be in VIP. 
69 
-·---- ----;mr.~I ~ 
Chapter 5 Conclusions 
This thesis examined issues relating to the genetic association mapping of T1D. 
1. In the assessment of the feasibility of association mapping in linked regions, it was 
noted that surprisingly strong allelic effects are expected from disease variants 
contributing to linkage, and association mapping could be successful with moderate 
sample sizes, provided that gene-gene and gene-environment interaction effects are 
modest. 
2. The evaluation of SNP density requirements for large-scale indirect association 
analyses showed that, for the study of common SNPs with MAP 2: 10 %, while 
sparse SNP maps are of some value for disease mapping, comprehensive 
association studies require densities of greater than one SNP per kb in some parts of 
the genome. 
3. The examination of four candidate genes/regions noted novel T1D associations 
with the HERV-Kl8 I CD48 locus (chromosome lq23) and with the VIP locus 
(chromosome 6q25), but not with SNPs flanking D2Sl52 in IDDM7 or with SNPs 
in PDCD2 and PSMBJ of IDDM8. The positive association findings need to be 
followed up in other datasets to establish their validity. If the replications provide 
support, then fine mapping and functional studies should be carried out to identify 
the disease casual variant. 
The field of human genetics is about to enter a very exciting phase. Up to now, association 
mapping for common diseases has almost always been on candidate genes or small 
regions. However, in the past few years, the availability of the human genome sequence 
(Lander et al. 2001), better understanding of the structure and utility of genomewide LD 
(Patil et al. 2001 ; Gabriel et al. 2002; Chapman et al. 2003), and advances in economical 
high throughput genotyping technology (Livak et al. 1995; Syvanen 2001), have brought 
the prospect of genomewide association mapping closer to practical reality (Copeman et al. 
1995; Risch and Merikangas 1996). Rapid increases in the number of SNPs in both public 
and private databases might allow direct association mapping based on perhaps 50,000 
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candidate functional polymorphisms to be conducted in the very near future. For indirect 
mapping, the International HapMap Project aims to provide LD and haplotype 
relationships for common SNPs throughout the genome (International HapMap 
Consortium 2003). From there, perhaps 500,000 htSNPs would be selected for genotyping 
and analyses. Important issues that need to be resolved for indirect mapping include (i) 
the optimal approach to htSNP selection and analyses across wide regions up to a full 
chromosome length, (ii) consideration of genomewide significance levels, (iii) the 
challenges of studying gene-gene interactions in the face of multiple testing issues, and (iv) 
the usefulness of haplotype maps for different but related populations. Affordable genome 
resequencing for individuals may even be possible in the foreseeable future (Schlotterer 
2004). Finally, plans should be made now for translating the soon-to-be-available genetic 
knowledge into improvements in clinical medicine and public health. One can certainly 
envisage significant potential for the analyses of gene-environment interactions, 
identification of high-risk groups, and for evaluating of the efficacy of drugs according to 
genotype. In the long term, the application of genetic knowledge will yield in new 
therapies, and may well extend well beyond that. 
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Appendix 1 
Details of SNPs in the HERVK-18 / CD48 locus 
OIL Nick name DbSNP Chromosome Variant 5' flanking 3' flanking 
Number 1 position 
DIL4949 rs3795324 rs3795324 157859903 A/C TCTATTTTACCTCATCTAGTTCCAG TTCTCAAATCATATAGGGCCAGGAG 
DIL4950 rs3766366 rs3766366 157866718 A/G AAACAGCAACGTTCTCAGAGGCCAG ATCCCTGATGACTGGGCATGACAGG 
DIL4951 rs3766367 rs3766367 157866933 GIA AGAGACTGCGTCTCATTTAGCTCCC CTTACTAAGGACTTGTCAGCCACTG 
DIL4952 rs3796502 rs3796502 157869522 TIA AACTCAAATCCCATAAGATTAAAAA TGGCAGAGAATTGACCAGATCAGAG 
DIL4953 rs2295615 rs2295615 157871550 CIG CTCATGATGTAGGTGCTGTTGTCCT TTTCTGGACCTTAGAGATGTACAGT 
DIL4938 HERV-SNP1 157884199 A/G ATGTCACTCAGGCCACGGGTAAATT TTTACAAGACTTTTCTTATCAAAGA 
DIL5197 K18-SNP2 157884370 A/G CAATGAATTCGNAACTATTATAGATT GGCACCTCGAGGTCAATTCTACCAC 
DIL6091 K18-SNP5 rs1313992 157885509 A/G TATGATTATAAATCTCATATTAATC TTGTGTGCCTGTTTTGTCTGTTGTT 
DIL6092 K18-SNP9 rs481433 157885823 CIT AAACTCNGGGTTAAATGGATTAAGGG GGTGCAAGATGTGCTTTGTTAAACA 
DIL6094 K18-SNP6 rs1265813 157885957 CIT CGCAGGGACCTCTGCCTAGGAAAGC AGGTATTGTCCAAGGTTTCTCCCCA 
DIL4954 rs3766369 rs3766369 157893653 A/G CTCTCATAAGATTAAATATTTAACA GCCTGTACAACCCTTTTTAGGAAGT 
DIL4955 rs352683 rs352683 157897231 A/G GATGAATACTTCACATCAGCCCCCA TCCCAAGGTCATACCAATGTCCTAT 
DIL4956 rs352684 rs352684 157898567 A/G AAGAGCATCACGGAAACTGAGAACA TTTTGTTTGAAGGTACATGAGTGCT 
DIL4957 rs352685 rs352685 157898628 CIG GGGAAGATTCATAGCTTCTACTGTA TCTCAGGGGGGCCAGTACTCAGAAA 
DIL4958 rs2070931 rs2070931 157898655 GIT CTCAGGGGGGCCAGTACTCAGAAAA AATAAGGGACCCTGATAGAGAATGT 
DIL7553 rs3753386 rs3753386 157899958 GIT GCTCATAGAAGTAGAGAGTAAAATT TGGTTATCAGAGGCTGGGAAGGGTA 
DIL7554 rs3753388 rs3753388 157900080 A/T CAGCATCCTGTAGCACTATGGAGTG ATACAGTTAAGAATAATTTAATGTA 
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Details of SNPs in the IDDM7 locus 
OIL Number Nick Name dbSNP Chromosome Variant 5' flanking 3' flanking 
2 position · 
D1L4897 rs1992898 rs1992898 187693683 A/G CCTTGTACCAGAAGCATAAAAATAG TTACTGAAATGCAGTATAGTGTTTA 
D1L4902 rs2197138 rs2197138 187696384 A/G CTAGCTGATCTTACTGTCAGAATCA TAATATTACTATTTGTAATATAATT 
D1L4896 rs201831 4 rs2018314 187987553 CIT AGTTCTTACTTTCCCGGCTCACAAC TATTTTAATCTTATTATATTTTTTA 
D1L4900 rs840569 rs840569 188375668 A/G TTTTACGTGTTCCAAGCATGAATTT CCTAAATATTCAGACAAAGAGAAGA 
D1L4614 c1590313 rs1528233 188409788 A/G ACACTCTCATGTACCTATCTCAACA TAGGCCAAACCTTATTAAACTAGCA 
D1L4481 rs696092 rs696092 188412757 A/G ATGTTTTCCTAATGATATAGAAGTA GATTGCATATTATACATCCTGTTCA 
D1L4526 rs3771095 rs3771095 188413655 CIT TTTTGTATTGATTCCAGTTTCTTCT AGAATTGCTTGAACCTATCAATCAA 
D1L4615 c2671025 rs698590 188417366 AfT ATCACAGCCAAGATGAAAAGTAGCA CTTTGGTGATTAAATGCATTGCTGT 
D1L4527 rs698588 rs698588 188417467 AIG TTTGAATATTTAAAAATTAGTTCAT GAATTAAAATCTGTTTCTGTAGATA 
D1L4528 rs858745 rs858745 188419350 CIT GCTATATGTATATTTAATTCCAAAC TCTCAAGCTGCCTTCTTATCAAGAA 
D1L4529 rs2308082 rs2308082 188421227 AAT I- AGAAACT AGAGTTGACAAT AGAGTT TATTCTATTAGCTATTTTATAAATA 
D1L4530 rs858750 rs858750 188421595 A/G GGACAGTTTCTGGAAGTCATTCCCA ACAATCACTTAACTATGCACTGAAG 
D1L4531 rs3815524 rs3815524 188426865 CIG AAGGATTAGAAGAAATTCAGCATTC TGTACTTTCTGTGAGATGGAATTGG 
D1L4533 rs3771089 rs3771089 188432689 CIT TTGTTTAGAGAGAGGAACTGCTTAT CATGCAAATATACATGTTTTTAGTA 
D1L4534 rs860846 rs860846 188437471 TIG TTAGCAGCATAATATCTAGTCATTC GTTTTTTCTTTTTCCTAAATACTAA 
D1L4901 rs3771084 rs3771084 188446176 A/G GATGGGGCATTCNCCCAAGACATCT GTAATTTTCTTAAAATATTTTAAAT 
D1L4535 rs1 398061 rs1398061 188460528 CIT AACCTTTTGGAGAAGAATTTAGGAA CTGCATGTTTAGTAAGCACCCAAGT 
D1L4537 rs3771074 rs3771074 188488253 TIG TATATCATGGCTGATTTACAATAAT TACGTGTTGCCTTTCTTAGCTGGAA 
D1L4538 rs3771073 rs3771073 188488760 CIG CCACCATAGGCCATTCTTTCTCTAA AGTCCGATTTAATTTGTCCATGACT 
D1L4539 rs3771072 rs3771072 188491991 CIG TAAGGAGAAATGGCAGATTTGAAAC GTGATAGGTATAAATGAATTGTGGT 
D1L4540 rs1355519 rs1355519 188511147 TIC TTGAGGTGCATATGCAAAATATCTG GTAATCATTGGTCTCAGTTTAATTA 
D1L4618 c2671085 rs1912847 188527816 CIT AAAAAATTCATCCACTAGGTTAGTA TGGTACTAGAAACAGTATCTCTTAG 
D1 L6766 TFPI-SNP40 rs763684 188536766 CIA CCCATAACNTCATTTTGTAAACCTCA ATATACACAATAAAAATTATTTTAA 
D1L6765 TFPI-SNP38 rs8176580 188537789 A/G TCAATGGAAAGGCCCAAATGGTTCT GGATTCACCTGCTGTTCTTGGTCTA 
D1L6764 TFPI-SNP28 rs8176531 188546250 CIT GCTTCTTACTATGATTCCTTCAATA TTGTACTATTAGATATTGTGTTTGC 
D1L6763 TFPI-SNP22 188551243 GTTT I- TTGTTGAAAT ACTGAGATTCAAATT AAGACATTTAATCTCATAAAAGCAA 
D1L6762 TFPI-SNP20 rs8176508 188553606 AfT TAAAGTTCTTGTATCCTCTGTTCAG TCATTTANAATTTCATAAAAAGTACA 
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Details of SNPs in the /DDM7 locus (continued) 
DIL Number Nick Name dbSNP Chromosome 2 Variant 5' flanking 3' flanking 
position 
D1L6761 TFPI-SNP13 rs8176605 188558653 TIC GTGCATACATGTGGGCATAGTAGAA AATAGACAATGGACACTCAGGAAGA 
D1L4617 c2671117 rs2300412 188570418 A/G TTTTATGGGATTAGATCTAACTTAT TTACTAGATCCTTTGGTGTCCTGGT 
D1L4619 c11891805 rs3755248 188572775 CIT TGGTGAGCTGAGCACCACCAGGTAT TCTCATTGTGGCTACACTCCTTAGA 
D1L4899 rs2033838 rs2033838 189071303 A/G TTGTTCAAGGTATCAAAGTCCTCAC ATGATGCCGAAGTGAAAATACACTC 
D1L4898 rs1354906 rs1354906 189649361 CIT TCCTCTTAGGTCCCGATGAATGCAA ATTCTATTTAAAATACCAAAAAATG 
Details of SNPs in the VIP locus 
DIL Number Nick Name DbSNP Chromosome 6 Variant 5' flanking 3' flanking 
position 
D1L6184 rs2756117 rs2756117 153097899 A/G TTGGTAGGTTGTTTAAAACCTGTCC TTGCTAGGCCCTTTCCACTCTTTGT 
D1L6185 rs3757070 rs3757070 153100712 A/G TCTTCCAATCTCGTATTTGTTATTA CCACCTGAGTGGCAAAAATTACTGA 
D1L6186 rs3799142 rs3799142 153103687 CIT TGACAACATATGATTCAGTAATATT TGAGTATTAATATTCACTACTGAGT 
D1L6187 rs3823082 rs3823082 153105313 CIT CTCCTGCGTTGCTTTGATAACTAAA AAAATGGTTCTATCTGAATAGTTCT 
D1L6188 rs688136 rs688136 153111052 CIT CTTTTTCAGAATTCTTGAAGGAAAA GATACGCAACATAATTAAATTTTGA 
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Details of SNPs in PDCD2 
OIL Number Nick Name dbSNP Chromosome 6 Variant 5' flanking 3' flanking 
position 
OIL1597 20015_533 170740536 A/T GTAAATGAGTAATTATGGGACATTC AATTCCTCATCCCCTATGTCTTTAA OIL 1596 20014_62 170740733 err TTAGCTGGGTGTGTTGGTGTGCACC GTAGTCCTGGCTAGCTACTCCAGAG OIL1595 20012_548 170742301 err AAGGGTTATGGAATGTAAGCCAAAA AAGGGTCTGGCCTAGGAGGCAGCAG OIL 1594 20011_908 rs3734763 170742421 A/G CCTTCAGAACTGATCTTGGTCAGCC GCGGCCCTGCTTACAGATGAGACAC OIL1593 20011_424 170742885 Grr ATACCATTATAGGTGGTATTCATGG ATGATCCTATTCTTGTAAAAATATT OIL1592 20011_267 rs8770 170743040 A/G AAAATAGAGGTGCAGAGATGTTGAC GATTGCTTACACAGTGTCTACTTAT OIL 1591 20010_143 170743410 err ATAATCCTGCTTTGTAGTATGAGGA TGAAAGACCAAGATCCCTATAATCA OIL1590 20010_487 rs7745933 170743738 err TATTCTGCCTATTCACTCTTTGAGT AGACTACTTCTAAGATTCCTCTCTG OIL 1589 20010_521 170743768 G/- TTTGTATAAAGTGATTCCATATCAG GTGGCTATTCTGCCTATTCACTCTT OIL 1588 20009_745 rs3173219 170744202 C/G TTCTGTGACAATGAGGATATCTACA TGCTCTCCACCTCCAGTGTGGTTAT OIL 1587 20009_1 60 rs960744 170744717 err GAAGGCATT A{A/-}GTGGCACACTGG ACAGCCAGGTCTGATGGGGGAACTG OIL1586 20009_147 170744730 Al- CTTTGAGGTGATTGAGAAGGCATTA GTGGCACACTGG{Crr}ACAGCCAG OIL 1585 20008_174 170744872 TI- AGAATTCTGCAATTAGAGCAGAGGC CATTCTTAGTCCCTTCACAATATAT OIL1584 20008_286 170744982 err TTACAGTGAAATTTACTTATGTTTG AGTAGTTTTCAAAACACTATGTTTC OIL 1583 20008_598 170745254 err GCCCCCCCGCCAGAAAGAAAAAAGG TATTTTTGCCCATTTCCAACAGGTA OIL 1582 20007R_49 170746049 A/G CTCCCAAAGTACTGGGATTACAGGC TGAGCCACTGCTCCAGGCCAGAAAT OIL 1581 20006_396 rs6928843 170746893 A/G ATTGGTAAATAAAAGGAAAGAGTTT CCTTCGAGGGGTACATAACTTAATT OIL 1580 20006_531 170747017 err TGGACAGTTTGAACATCCACAAGGA GCTAACTGCATCAGATATGTTTAAT OIL 1579 20006_630 170747112 A/G ATGTGGGAACATGGTCATATCAAAG TTAAGGATAAGGATTACTAGGGCCA OIL 1578 20005_38 170747302 Grr TTGAGATGGTTGTGTGTGTATTGGG GGAAAGGAAACGAGTAATTATGTTG OIL1577 20005_302 170747552 A/T GTGTAAATGTGACTGTGGAACTGTA GAGTATTTTAAGATTATGGAGTAAA OIL3987 20004_91 170747953 err TATGAACTACAAACCAGTAAGCTGA GTTTTCATTTTGAGTCTATAAATCT OIL1576 20004_152 rs2066954 170748002 A/C AAATTTTACAATTTGAGCCTTGAGC ATACACAAAACCACCACAAAATTAG OIL 1575 20004_545 rs2072917 170748365 Grr GGTAAGTTCCTCTGGGTCGCAGATC GTTTCTCGGGTCGGGATAGTGTGAG OIL1574 20003R_221 170748609 A/G CATTCATTAAGTGGTTAAACATAAT CTTGGAAGAAAGGGCTCCATGTGCC OIL3988 20003_1 34 rs4140614 170748993 A/- TTAGGAAAGGTATAGTACTTTAAAA TTTTCATGCCTGGAACACCTTTGTA OIL 1573 20102_97 rs414061 5 170749357 err TGTTTGAAGATAAAACTTTTCTCTG ATTCTTTTTTAGTTTTTAGGAATCA OIL 1572 20103_insdel 170749429 TGAG/- ACTTTCATTTCTTTTTTGTTGTTGT TATTTTCAGTTTTACGTGCAGAGGA OIL 1571 20102_282 170749520 A/G TAACTCAAACCACCTCTAGGAGGCA CTCAGTTGCGTGTACCGGACGAAAT OIL1570 20017_114 rs734249 170750527 A/C GGTGGACACCAGCAGGGAAGGTTTG GGGAGGGCTCTGCCTCCCTGGCGGC 
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Details of SNPs in PDCD2 (continued) 
OIL Number Nick Name dbSNP Chromosome 6 Variant 5' flanking 3' flanking 
position 
OIL1569 20018R_455 170751501 CIT GTTAACTTTTGGTTTACAATGTAAA GTTTATTTAAAAACAGACATTATTT OIL 1568 20019_247 170751802 A/G GGTGGCTCATGCCTGTAATCCCAGC CTTTGGGAAGCTGAGACGGACAGAT OIL 1567 20019_622 rs2092309 170752140 C/G TTGCTTCCCCTCCCCTATTGTTTAC TAAAAATGATAATTCACTGAGCCAG OIL 1566 20019_659 170752173 A/T TTTAAGGTGCGCCTGAGACAAATGC TATCTAATTGCTTCCCCTCCCCTAT OIL1565 20019_732 170752243 A/G ACCTCCCTTAAAATTTGCCCACAAG AAATTCCTTGTGGATAAAGGACAGA OIL1564 20020R_152 170752372 A/C AAGGAAAATAAAACTCAGGACCACA AATCACTAAACCAAAGGGTAAAGTC OIL1563 20021F_330 rs1016536 170753071 A/C CTTCGCAAGATAAATTTTCTAAATT ACTGAGACCTGTCTCCAATTTTTGG OIL1562 20021F_245 rs4507568 170753153 A/G ATAAAACCACC{C/G}TGTGCTCTGACT TCTTAGGT ACATGTCGTCAGGACCT OIL 1561 20021F_232 170753166 C/G TCTCCCTAAAATGTATAAAACCACC TGTGCTCTGACT{A/G}TCTT AGGT A 
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Details of SNPs in PSMBJ 
DIL Number Nick Name dbSNP Chromosome 6 Variant 5' flanking 3' flanking position 
D1L4062 50001_154 170718965 A/C CCGCCGTGCAGCCCTCCAGGAGCAA GACTAGCGTGAGATAGAGAGGCCGG D1L4063 50001 _280 170718845 CIT CAAGTGTCGGATCCGCAGGCGCAGC GTGCGATGTTGTCCTCTACAGCCAT D1L4064 50001_316 rs12717 170718809 C/G GTCCTCTACAGCCATGTATTCGGCT CTGGCAGAGACTTGGGGATGGAACC D1L4065 50001_575 rs4710839 170718560 C/G CGGTCTCCCTGCCGTCCTCTCATGC CTGTGTTTCCCTCTTCAGGCT D1L4066 50001_597 170718538 A/C GC{C/G}CTGTGTTTCCCTCTTCAGGCT GCTTTGCTCAAGTTT ACTTGGTGAT D1L4067 50002_20 170714852 A/G AGGGGTCATTCTCTTCCC CTCATCTTTC{CIT}TCTTCCCATTTGT D1L4068 50002_31 170714841 CIT TCATTCTCTTCCC{A/G}CTCATCTTTC TCTTCCCATTTGAATCATGTTTTTG D1L4069 50002_141 170714737 A/G GTAGGGATAGGATTACCACCCTGGA AATTAATTTTTTTCTTTTTTCCTCA D1L4070 50002_324 rs2076319 170714554 A/G TTTCACAATGCCTTTGTAATGATTT ATGTTGTGAGAGTTTCTACTTCTAA D1L4071 50002_492 170714391 CIT GTATTCAGGGTACCAAAAGTGCTTT GGTAACCTAAATGTGTTCCCCCCCC D1L4078 50003_199 170711898 CIT CCCTCCTCCCCAGAAGGGTGACTGT TGTCCCATTACCATTTAGGGAATAG D1L4079 50003_236 170711 861 A/G CATTTAGGGAATAGTGGGAATCAGA TTTTAAATTTAAAATTGCCGAAGAT D1L4080 50003_417 170711685 A/G CAAGACTAAAGGTAGATGCTTTTGT CATTTCTACACTATTTTAAATTAAT D1L4081 50004_80 170709540 CIT CCTGAGATAAGGGTGGTATGGAAAA AGAGTCTAAACCAGAGAGCTGAGGG D1L4082 50004_570 rs1474642 170709070 CIT ACAATTCTCATTTCATTTCTGATAA GAAAGTGATGAAGAAACTGAAGCTA D1L4083 50005_101 170703019 A/G CCAAGGTGATAGTGCGTTTTGTGTC CGTTTTGACCTGATTTATTTTTGCG D1L4084 50006_52 rs3823299 170701114 A/G AGTCTGAAGGACATTTTAATTTTGT TAGTATTTTCATCACAAATCCTCGT D1L4085 50010_335 170699334 C/G AAAATGTAGATTTGAAATTGGGATA TCTACAGTTTTTAGTTGGGACATTG D1L4086 50010_366 170699363 CIT ACAGTTTTTAGTTGGGACATTGGGA AGTTAATTTTAGGTGTCAACTTGAC D1L4087 50011R_85 170698590 GIT ACTGTGGACTACAGCAGGGAGCTAT GCTGCATGGGGAAATATGGAGACAC D1L4088 50013_128 170698064 A/G TCATTCCTTGTATTTGTGAATTTCA ACTGTAACTGGAAGATTCCCTGTAT 
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